DEVELOPMENT AND LICENSE AGREEMENT

Exhibit 10.11(b)

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

DEVELOPMENT AND LICENSE AGREEMENT

This Development and License Agreement (“AGREEMENT”) is made and entered into June 12, 2007 (the “EFFECTIVE DATE”) by and between SciDose, LLC, having its principal place of business at 000 Xxxxxxxxxx Xxxx, Xxxxxxx, XX 00000 (“SCIDOSE”); and Eagle Pharmaceutical, Inc. having its principal place of business at 000 Xxxxxxxx Xxxxx Xxxx, Xxxxxxxxx Xxxx, XX 00000 (“EAGLE”). SCIDOSE and EAGLE may be referred to herein individually as a “PARTY” and collectively as the “PARTIES.”

RECITALS

WHEREAS, EAGLE is in the business of developing, making, marketing and selling, and possesses confidential proprietary information related to, pharmaceutical products for the treatment of diseases; and

WHEREAS, SCIDOSE is engaged in the research and development of, and possesses confidential proprietary information related to, pharmaceutical and therapeutic products, processes and technologies, including SCIDOSE’S proprietary formulation of argatroban and [*]; and

WHEREAS, EAGLE desires to obtain ownership of, or license to, certain of SCIDOSE’S intellectual property rights related to the PRODUCTS (as defined herein), in the TERRITORY (as hereafter defined), under the terms and conditions specified herein; and

WHEREAS, SCIDOSE desires to assign or license such intellectual property rights to EAGLE, under the terms and conditions specified herein.

NOW, THEREFORE, in consideration of the foregoing and the covenants and promises contained in this AGREEMENT, the PARTIES agree as follows:

AGREEMENT

1. Definitions

1.1 “505(b)(2)” means a 505(b)(2) Application filed with the FDA, or any foreign equivalent filed with the FDA to obtain MARKETING AUTHORIZATION for the PRODUCT in such country.

1.2 “AFFILIATE” means, with respect to any other person or entity, any other person or entity that directly or indirectly controls, is controlled by, or is under common control with, such person or entity. For purposes of this definition only, “control,” “controlled by” and “under common control with” shall mean the possession of the power to direct or cause the direction of the management and policies of an entity, whether through the ownership of voting stock or partnership interest, by

contract or otherwise. In the case of a corporation, the direct or indirect ownership of fifty percent (50%) or more of its outstanding voting shares or the ability otherwise to elect a majority of the board of directors or other managing authority of the entity shall in any event be deemed to confer control, it being understood that the direct or indirect ownership of a lesser percentage of such shares shall not necessarily preclude the existence of control.

1.3 “ASSIGNED PATENTS” means (i) the PATENT APPLICATIONS set forth in Schedule I, all PATENT APPLICATIONS claiming priority to such PATENT APPLICATIONS, any of their progeny and any PATENTS issuing from, directly or indirectly, or based upon any of the foregoing, and (ii) the inventions described or claimed in any of the foregoing.

1.4 “CLAIMS” has the meaning set forth in Section 9.1.1.

1.5 “CONFIDENTIAL INFORMATION” has the meaning set forth in Section 6.1.

1.6 “CONTROL(LED)” means the ability to grant a license or sublicense as provided for herein without violating the terms of any agreement or other arrangement with any THIRD PARTY.

1.7 “COST OF GOODS” means, in respect of any Product, the amount paid by EAGLE to its contract manufacturer for the manufacturing and release of such finished PRODUCT including the cost of the active pharmaceutical ingredient, raw materials and packaging materials used in such finished PRODUCT.

1.8 “DEFAULT” has the meaning set forth in Section 8.2.2.

1.9 “DISCLOSING PARTY” means the PARTY disclosing CONFIDENTIAL INFORMATION to the other PARTY hereunder.

1.10 “DOLLAR(S)” means United States dollars.

1.11 “FDA” means the United States Food and Drug Administration, or any successor entity that may be established hereafter which has substantially the same authority or responsibility currently vested in the United States Food and Drug Administration.

1.12 “FIRST COMMERCIAL SALE” means, with respect to a PRODUCT, the first sale by EAGLE or its LICENSEES to a THIRD PARTY following receipt of a MARKETING AUTHORIZATION for such PRODUCT; provided, however, that the PRODUCT shipped by EAGLE or its LICENSEES to a THIRD PARTY prior to receipt of MARKETING AUTHORIZATION therefor shall be deemed for the purposes hereof a FIRST COMMERCIAL SALE to the extent such PRODUCT is

sold to a THIRD PARTY for sale after such MARKETING AUTHORIZATION is obtained.

1.13 “GROSS PROFIT” means NET SALES minus COST OF GOODS minus SALES FORCE COSTS.

1.14 “GROSS PROFIT MARGIN” means the fraction, expressed as a percentage, the numerator of which is the GROSS PROFIT and the denominator of which is the NET SALES.

1.15 “EAGLE INDEMNITEE” has the meaning set forth in Section 9.1.1.

1.16 “EAGLE KNOW-HOW” means all KNOW-HOW CONTROLLED by EAGLE that is necessary or useful for SCIDOSE in connection with SCIDOSE’S performance of its obligations under this AGREEMENT. EAGLE PATENT RIGHTS are excluded from the definition of EAGLE KNOW-HOW.

1.17 “EAGLE PATENT RIGHTS” means all PATENTS and PATENT APPLICATIONS CONTROLLED by EAGLE that are necessary for SCIDOSE in connection with SCIDOSE’S performance of its obligations under this AGREEMENT.

1.18 “INVENTIONS” means any and all ideas, concepts, methods, procedures, processes, improvements, inventions and discoveries, whether or not patentable, that are conceived or made in the course of the performance of activities conducted in connection with this AGREEMENT including the development or manufacture of the PRODUCTS.

1.19 “JOINT INVENTION” has the meaning set forth in Section 10.3.

1.20 “JOINT PATENT APPLICATIONS” has the meaning set forth in Section 10.5.

1.21 “KNOW-HOW’ means all technical, scientific and other know-how, data, materials, information, trade secrets, ideas, formulae, inventions, discoveries, processes, machines, manufactures, compositions of matter, improvements, protocols, techniques, works of authorship, and results of experimentation and testing (whether or not patentable) in written, electronic, oral or any other form.

1.22 “LAW(S)” means any applicable local, state or federal rule, regulation, statute or law in any jurisdiction relevant to the activities undertaken pursuant to this AGREEMENT.

1.23 “LICENSEE” means any person or entity, including EAGLE AFFILIATES, to which EAGLE grants a license under the ASSIGNED PATENTS or LICENSED SCIDOSE TECHNOLOGY to sell, have sold and/or import the PRODUCT.

1.24 “MARKETING AUTHORIZATION” means, with respect to any Product, the requisite governmental approval (e.g., ANDA or 505(b)(2) or equivalent) for the marketing and sale of such PRODUCT in the TERRITORY.

1.25 “NET SALES” means, with respect to any Product, the amount invoiced by (or in the absence of an invoice, the amounts payable to) EAGLE or its AFFILIATES for the sale to THIRD PARTIES of such PRODUCT less the following: (i) customary administration fees, drug wholesaler fees, charge-backs, rebates (including Medicaid, Medicare and similar rebates) and trade and customary quantity discounts actually allowed and taken, including shelf stock adjustments, cash and volume discounts, chargebacks, promotional allowances, inventory obsolescence; (ii) allowances actually given for returned PRODUCT; (iii) documented freight, postage, shipping costs and insurance paid by EAGLE (if separately stated); (iv) government-mandated and other rebates customary in the industry; (v) value added tax, sales, use or turnover taxes, excise taxes and customs duties and (vi) if applicable, expenses related to (A) PRODUCT recalls in accordance with Section 7.4, (B) infringement litigation in accordance with Sections 11.1.3, 11.2.2(b) and/or 11.2.3(a), and (C) marketing costs (other than SALES FORCE COSTS) directly related to Argatroban and/or [*] (or, as applicable, the REPLACEMENT PRODUCTS related thereto). NET SALES shall be deemed to accrue upon the date of the invoice for a PRODUCT. In addition, NET SALES by EAGLE hereunder are subject to the following, as accrued on EAGLE’s book in good faith:

(a) In the case of pharmacy incentive programs, hospital performance incentive program, charge backs, disease management programs, similar programs or discounts on “bundles” of products, all discounts and the like shall be allocated proportionately based on sales of comparable products to THIRD PARTIES on a standalone basis; and

(b) In the case of any sale or other disposal of the PRODUCT by EAGLE to an AFFILIATE for resale, the NET SALES shall be calculated as above on the value charged or invoiced on the first arm’s length sale to a THIRD PARTY;

1.26 “NON-DISCLOSURE AGREEMENT” means that agreement entered into between the PARTIES on April 13, 2006 providing for confidential treatment of the PARTIES’ information.

1.27 “PATENT” means: (i) any letters patent and utility models including any extension, substitution, registration, confirmation, reissue, supplemental protection certificate, re-examination or renewal thereof; and (ii) to the extent valid and enforceable rights are granted by a governmental authority thereunder, a PATENT APPLICATION.

1.28 “PATENT APPLICATION” means an application for letters patent, including a provisional application, converted provisional application, continuation application, a continued prosecution application, a continuation-in-part application, a divisional application, a re-examination application, and a reissue application, including the applications listed on Schedule 1 hereto.

1.29 “PERSON” means any natural person, corporation, company, partnership, limited partnership, limited liability company, firm, association, trust, government, governmental agency, or any other entity, whether acting in an individual, fiduciary or other capacity.

1.30 “PRODUCT(S)” means (i) all parenteral formulations of Argatroban and [*] and (ii) two molecules to be determined by at later date in accordance with Section 2.7.

1.31 “PRODUCT FAILURE” means, in respect of any PRODUCT, (i) rejection by the FDA of the filing of the 505(b)(2) or ANDA application, as applicable, (ii) failure to receive MARKETING AUTHORIZATION by the FDA following such application filing or (iii) the failure to complete the milestone in respect of such Product set forth in Schedule Ill within thirty (30) days of the date set forth on Schedule Ill (as the same may be extended by Agreement of the PARTIES).

1.32 “RECIPIENT” means the PARTY receiving CONFIDENTIAL INFORMATION hereunder.

1.33 “REPLACEMENT PRODUCT” means, (i) with respect to Argatroban and [*], a 505(b)(2) PRODUCT and (ii) with respect to the THIRD AND FOURTH PRODUCTS, a PRODUCT with an anticipated ANDA filing, in each case selected by the Development Committee to replace such PRODUCT which is subject to a PRODUCT FAILURE.

1.34 “RESPONSIBLE PARTY” has the meaning set forth in Section 10.5.

1.35 “ROYALTY RATE” means, (i) with respect to Argatroban and [*], [*] and (ii) with respect to the THIRD AND FOURTH PRODUCTS, [*].

1.36 “ROYALTY TERM” means, with respect to a PRODUCT, the period of time commencing on the date of the FIRST COMMERCIAL SALE of a PRODUCT and expiring upon the later of: (a) ten (10) years thereafter; and (b) the expiration date of the last VALID PATENT CLAIM covering the manufacture, use, importation or sale of the PRODUCT in the TERRITORY.

1.37 “SALES FORCE COSTS” means the costs of any hospital sales force hired to market and sell the PRODUCTS (provided, however, that Eagle shall have no

obligation to hire a hospital sales force for the marketing and selling of Argatroban or [*]).

1.38 “SCIDOSE INDEMNITEE” has the meaning set forth in Section 9.1.2.

1.39 “SCIDOSE KNOW-HOW’ means all existing and future KNOW-HOW owned or CONTROLLED by SCIDOSE, that is necessary or useful for EAGLE to develop, make, have made, use, offer for sale, sell, have sold and import the PRODUCTS. SCIDOSE PATENT RIGHTS are excluded from the definition of SCIDOSE KNOW-HOW.

1.40 “SCIDOSE LICENSED TECHNOLOGY” means, collectively, the SCIDOSE PATENT RIGHTS and the SCIDOSE KNOW-HOW, excluding the ASSIGNED PATENTS.

1.41 “SCIDOSE PATENT RIGHTS” means all of the existing and future PATENTS and PATENT APPLICATIONS owned or CONTROLLED by SCIDOSE which claim the composition, development, manufacture, offer for sale, sale, import or use of the PRODUCTS, and that are necessary or useful to develop, make, have made, use, sell, have sold or import the PRODUCTS.

1.42 “SOLE INVENTION” has the meaning set forth in Section 10.3.

1.43 “SUBLICENSEE” means any person or entity, including its AFFILIATES, to which EAGLE grants a sublicense to sell, have sold and/or import the PRODUCT pursuant to the license set forth in Section 2.2.

1.44 “TERM” has the meaning set forth in Section 13.1.

1.45 “TERRITORY” means all of North America, including the United States, its territories and possessions (including, Puerto Rico, Virgin Islands and Guam) and Canada.

1.46 “THIRD AND FOURTH PRODUCTS” has the meaning set forth in Section 2.7.

1.47 “THIRD PARTY” means any entity other than SCIDOSE, EAGLE and their respective AFFILIATES.

1.48 “VALID PATENT CLAIM” means either: (a) a claim of an issued and unexpired PATENT that is included in the ASSIGNED PATENTS or the SCIDOSE LICENSED TECHNOLOGY and covering the manufacture, use, import or sale of a PRODUCT, which PATENT has not (i) expired or been canceled with prejudice, (ii) been declared invalid by an irreversible and unappealable decision of a court or other appropriate body of competent jurisdiction, (iii) been admitted to be invalid or unenforceable through reissue, disclaimer, or otherwise, or (iv) been abandoned; or (b) a claim filed and kept pending in good faith that is

included in a PATENT APPLICATION that is included in the ASSIGNED PATENTS or the SCIDOSE LICENSED TECHNOLOGY and covering the manufacture, use, import or sale of a PRODUCT, which PATENT APPLICATION has not been (i) cancelled with prejudice, (ii) withdrawn from consideration without the ability to resubmit or re-file, (iii) finally determined to be unallowable by the applicable governmental authority, or (iv) abandoned.

2. Assignment and Licenses

2.1 Assignment to EAGLE. SCIDOSE hereby transfers, sells and assigns, and agrees to transfer, sell and assign, to EAGLE all right, title and interest in the ASSIGNED PATENTS and all intellectual property rights therein, including all income, royalties, damages, claims, and payments now or hereafter due or payable with respect thereto, and in and to all causes of action, either in law or in equity for present or future infringement based on the ASSIGNED PATENTS. SCIDOSE shall, at EAGLE sole cost and expense, take such further actions and provide such cooperation and assistance (including, without limitation, the execution and delivery of any all affidavits, declarations, oaths, exhibits, assignments, powers of attorney or other documentation), requested by EAGLE to more fully and effectively effectuate the purposes of the above assignment.

2.2 License to EAGLE. SCIDOSE hereby grants to EAGLE (i) an exclusive, perpetual, royalty-bearing (as provided in Section 3.2) license, with the right to grant sublicenses, under SCIDOSE’S interest in the SCIDOSE LICENSED TECHNOLOGY solely to develop, make, have made, use, sell, have sold, offer for sale or import the PRODUCTS in the TERRITORY. Upon expiration of the ROYALTY TERM, the foregoing license shall be royalty-free. In the event that any technology is licensed to SCIDOSE that is useful for the PRODUCTS, or an improvement to the PRODUCTS, to the extent permitted by SCIDOSE’s agreement with the licensor, SCIDOSE shall promptly notify EAGLE of such technology and offer EAGLE the use of such technology to the greatest extent permitted by such agreement. In the event that EAGLE elects, in its sole discretion, to use such technology, then the PARTIES shall negotiate in good faith a commercially reasonable amount that EAGLE will reimburse SCIDOSE, which amount shall represent a portion of any fees that SCIDOSE must pay under such agreement, based on EAGLE’s proportional use under the license in connection with the PRODUCTS as compared to SCIDOSE’s aggregate use under the license for any purpose.

2.3 SCIDOSE Research Rights and Limitations. Notwithstanding anything to the contrary in this AGREEMENT and without limiting any other retained rights, the license granted under Section 2.2 shall be subject to the retained right of SCIDOSE and its AFFILIATES: (i) to practice the SCIDOSE LICENSED TECHNOLOGY for the conduct of research and development of products (other than the Product) that it is developing either itself or with others; and (ii) to

develop, make, have made, use, sell, offer for sale, import and license products other than the PRODUCTS; provided, however, that with respect to the foregoing clauses (i) and (ii), such products do not violate the restrictions in Section 2.6 or 8.4.

2.4 No Implied Rights or Licenses. Neither PARTY grants to the other any rights or licenses, including without limitation to any SCIDOSE LICENSED TECHNOLOGY or other intellectual property rights, whether by implication, estoppel or otherwise, except to the extent expressly provided for under this AGREEMENT.

2.5 License to SCIDOSE. EAGLE hereby grants to SCIDOSE a non-exclusive, worldwide (to the extent of EAGLE’s rights), royalty-free license under (a) EAGLE KNOW-HOW and EAGLE PATENT RIGHTS, if any, and (b) the SCIDOSE LICENSED TECHNOLOGY that is licensed exclusively to EAGLE hereunder, in each case only to the extent useful or necessary for SCIDOSE to fulfill its obligations under this AGREEMENT or for the manufacture or sale of the PRODUCTS outside the Territory.

2.6 Mutual Covenant. Each PARTY covenants and agrees that (i) it and its AFFILIATES shall not use or practice the intellectual property rights licensed under this AGREEMENT except as expressly permitted by this AGREEMENT and (ii) any use or practice of the intellectual property rights licensed under this AGREEMENT except as expressly permitted by this AGREEMENT that results in material harm to the other PARTY shall constitute a material breach of this AGREEMENT. Notwithstanding the foregoing, each PARTY covenants and agrees to cease any non-permitted use and to take all actions necessary to assign to the other PARTY any inventions made through use or practice of such PARTY’S intellectual property rights outside the scope of the license rights granted hereunder.

2.7 Selection of Additional Products. Within ninety (90) days after the EFFECTIVE DATE, each PARTY shall nominate up to four candidates as proposed additional PRODUCTS. Thereafter the PARTIES shall mutually agree in good faith upon the selection of the two additional PRODUCTS (the “THIRD AND FOURTH PRODUCTS”) to be included in this Agreement. Criteria for the selection of the additional PRODUCTS shall include (i) market potential; (ii) the potential for the entry of future competing products; (iii) the ability of the PARTIES to develop non-fringing formulations; (iv) the costs of development; and (v) the projected time to market. The failure of the PARTIES to select either of the THIRD AND FOURTH PRODUCTS on or before [*] days after the EFFECTIVE DATE will be deemed a PRODUCT FAILURE for purposes of this Agreement.

3. Milestones: Royalty Payments: Royalty Reports

3.1 Milestone Payments.

3.1.1 EAGLE shall pay to SCIDOSE the respective milestone payments in accordance with and on the respective dates provided in Schedule II hereto. Such milestone payments shall be in addition to any royalty or other payments due under this AGREEMENT and are allocated among the PRODUCTS as follows:

Argatroban		[*]
[*]		[*]
THIRD PRODUCT		[*]
FOURTH PRODUCT		[*]

3.1.2 In the event of any PRODUCT FAILURE, then, subject to Sections 3.1.3 and 3.1.4, (a) if such PRODUCT FAILURE relates to Argatroban or [*], then SCIDOSE shall be obligated to refund to EAGLE an amount equal to the portion of all milestone payments paid by EAGLE and allocated to such PRODUCT, and (b) if such PRODUCT FAILURE relates to either of the THIRD AND FOURTH PRODUCTS, SCIDOSE shall refund to EAGLE an amount equal to the portion of all milestone payments paid by EAGLE and allocated to such PRODUCT. In the event of a PRODUCT FAILURE with respect to any PRODUCT prior to payment of all milestone payments, future milestone payments in respect of such PRODUCT, if any, shall be allocated towards a REPLACEMENT PRODUCT.

Example: EAGLE pays [*] to SCIDOSE upon execution of this Agreement and an additional [*] on [*] in accordance with Schedule II. On [*], a PRODUCT FAILURE occurs with respect to Argatroban. An amount equal to [*] of the milestone payments previously made by EAGLE to SCIDOSE (i.e., [*]), will be required to be refunded by SCIDOSE to EAGLE, subject to Section 3.1.3

3.1.3 In the event SCIDOSE does not repay any amounts to be refunded by it by the later of [*] or the date of the milestone failure, SCIDOSE shall issue to EAGLE a promissory note in the principal amount of the unpaid amounts which shall be due and payable on [*]. Interest on the unpaid principal portion of such note shall accrue at the rate of [*] per year and shall be due and payable with all unpaid interest on the maturity date. Principal and interest under the note may be pre-paid at anytime without premium or penalty. Upon repayment in full of such amount, (i) the license granted pursuant to this Agreement with respect to the LICENSED TECHNOLOGY for the failed PRODUCT shall terminate and EAGLE shall assign the ASSIGNED PATENTS related solely to the failed PRODUCT to SCIDOSE and (ii) the license granted by EAGLE pursuant to Section 2.5 of this Agreement for the failed PRODUCT shall terminate.

3.1.4 Notwithstanding any other provisions the provisions of this Section 3.1, all milestone shall be deemed met and no refund of any milestone payment shall be payable to EAGLE in the event that, as of [*], payments are received from any

THIRD PARTY with respect to any PRODUCT which results in payment to EAGLE of at least [*]. In the event that, as of [*], payments are received from THIRD PARTIES from PRODUCTS which total in the aggregate less than [*], the amount to be refunded to EAGLE pursuant to Section 3.1.2 shall be reduced by an amount equal to the positive difference, if any, between (a) the amount to be refunded to EAGLE pursuant to Section 3.1.2 and (b) the difference between (i) [*], less (b) the total payments received by EAGLE from any such THIRD PARTY.

Example: Assume that the total payments received by EAGLE with respect to all PRODUCTS is [*] and that SCIDOSE has not refunded to EAGLE any milestone payments paid and allocated to the failed Argatroban PRODUCT (i.e., [*]). The amount to be refunded [*] shall be reduced by an amount equal to the positive difference, if any, between (a) the amount to be refunded to EAGLE pursuant to Section 3.1.2 [*] and (b) the difference between (i) [*], less (ii) the total payments received by EAGLE from any such THIRD PARTY [*], or [*]. Therefore, the amount to be refunded would equal [*].

3.2 Royalties. For the applicable ROYALTY TERM for each PRODUCT, EAGLE shall pay SCIDOSE royalties on sales of PRODUCTS by EAGLE and its AFFILIATES in the TERRITORY in an amount equal to the ROYALTY RATE times the GROSS PROFIT from the number of units of PRODUCTS sold; provided, however, that, if, at any time during the first ten (10) years after the FIRST COMMERCIAL SALE of such PRODUCT, there is no VALID PATENT CLAIM covering the manufacture, use, import or sale of a PRODUCT in a country in the Territory, then (i) with respect to Argatroban and [*] (or any 505(b)(2) REPLACEMENT PRODUCT, as applicable), the ROYALTY RATE shall be reduced to [*] in such country and (ii) with respect to the THIRD AND FOURTH PRODUCTS (or any ANDA REPLACEMENT PRODUCT, as applicable), the ROYALTY RATE shall be reduced to [*] in such country.

3.3 Reports. EAGLE shall notify SCIDOSE in writing within forty-five (45) days after the FIRST COMMERCIAL SALE of any PRODUCT in the TERRITORY. Commencing with the FIRST COMMERCIAL SALE of any PRODUCT in the TERRITORY, EAGLE shall furnish to SCIDOSE within thirty (30) days of the end of each calendar quarter, or as of the end of each calendar year, a written report (due in conjunction with the corresponding royalty payment equal to the ROYALTY RATE times the GROSS PROFIT from the number of units of PRODUCTS sold during that past quarter) showing, according to the volume of units of the PRODUCTS sold (by PRODUCT and SKU) during the reporting period: (a) the gross invoiced sales of the PRODUCTS sold during the reporting period, and the amounts deducted therefrom to determine GROSS PROFITS, COST OF GOODS and NET SALES from such gross invoiced sales (including with specificity, the applicable deductions therefrom; and (b) the accrued royalties

paid or payable for such period. Any royalty payments for such prior fiscal year payable to SCIDOSE which were not previously paid shall be paid to SCIDOSE on the date such annual report is due.

4. Product Development; Commercialization

4.1 Development Committee. The PARTIES agree to work together in good faith in the collaboration under this Agreement and to keep each other reasonably informed of its activities hereunder. Additionally, and in support of the foregoing, promptly after the Effective Date, the PARTIES will form a four-member committee (the “Development Committee”), equally represented by EAGLE and SCIDOSE, for the management of the development of the PRODUCTS, which will consist of the Chief Executive Officer and Chief Scientific Officer of each of EAGLE and SCIDOSE. Each Party shall have the right, from time to time, to substitute new members, on a permanent or temporary basis, for any of its previously designated members of the Development Committee. Each Party shall bear its own costs associated with participation in the Development Committee.

4.1.1 The Development Committee shall generally oversee and facilitate the development of the Products. Each party shall promptly provide the other and the Development Committee with a copy of any FDA correspondence within 48 hours of receipt thereof and it will be the responsibility of EAGLE, with the oversight and approval of the Development Committee, to create an appropriate response thereto.

4.1.2 During the Term, the Development Committee shall meet at least once each calendar quarter or at such other frequency as the Development Committee determines. The PARTIES shall meet on a date and time and at a location determined by the Development Committee; the PARTIES anticipate alternating meetings between the Party’s respective sites. Upon written notice by either Party to the other that a meeting is required or requested, a meeting will be held within thirty (30) calendar days of such notice on a date and time and at a location to be agreed upon by the PARTIES, or sooner if warranted by the circumstances. Notices requesting such a meeting shall include adequate information describing the activity to be reviewed. Any meetings of the Development Committee may be held in person at a location to be agreed to by the PARTIES, or by videoconference to teleconference.

4.1.3 In the event of a PRODUCT FAILURE, the Development Committee shall select a REPLACEMENT PRODUCT within one hundred twenty (120) days of such failure. In the event the Development Committee fails to select the REPLACEMENT PRODUCT within such period, EAGLE shall be entitled to a refund in accordance with Section 3.1.2.

4.2 Approval of the Product. Following, and subject to, the successful completion of the development to the reasonable satisfaction of EAGLE and SCIDOSE according to the criteria to be developed by the Development Committee, including obtaining favorable patent opinions and successful completion of any required pivotal biostudy, as applicable EAGLE shall prepare and submit the ANDA for the THIRD AND FOURTH PRODUCTS to the FDA as soon as reasonably practical. SCIDOSE shall use commercially reasonable efforts to assist EAGLE in the preparation and filing of the 505(b)(2) or ANDA applications and any follow-up communications with the FDA and shall promptly comply with all of EAGLE’s reasonable requests for information relating thereto. Each of the PARTIES shall promptly provide the other and the Development Committee with copies of all documents and correspondence received from regulatory authorities that relate to obtaining MARKETING AUTHORIZATION and each of the PARTIES shall use commercially reasonable efforts to obtain permission for the other party to attend all meetings with regulatory authorities in respect thereof.

4.3 Commercialization. The PARTIES hereby acknowledge that, during the Term, Eagle shall be the sole and exclusive distributor for the PRODUCTS in the Territory, either directly or through its AFFILIATES and/or SUBLICENSEES. All activities related to the sales and marketing of the Products in the Territory, including the launch date of such PRODUCT, will be the sole responsibility of Eagle. Eagle shall arrange for the manufacture, testing, packaging, labeling, transportation and storage of Eagle’s requirements of commercial supplies of the PRODUCTS hereunder from a third-party contract manufacturer (such third-party contract manufacturer being referred to hereafter as the “Third-Party Supplier”). Eagle may grant a right to a Third-Party Supplier to make, test, package, label, store and transport the PRODUCTS for sale by Eagle in the Territory hereunder.

4.4 Patent Marking and PRODUCT Marking.

(a) EAGLE shall place appropriate patent and/or patent pending markings on the PRODUCT or the packaging therefor. The content, form, size, location and language of such markings shall be in accordance with the LAWS and practices of the country in which the applicable units of the PRODUCT are distributed.

(b) EAGLE shall be responsible for all packaging (non-commercial and commercial) and labeling of the PRODUCT.

5. Records; Audits; Payment Terms

5.1 Records. EAGLE shall keep complete and accurate records in sufficient detail to make the reports required hereunder to properly reflect all gross sales, GROSS PROFITS and NET SALES of the PRODUCTS on which EAGLE is required

hereunder to pay royalties and to verify the determination of all amounts payable hereunder.

5.2 Audits. Not more than once per calendar year, upon the written request of SCIDOSE and not less than thirty (30) business days prior notice, EAGLE shall permit an independent certified public accounting firm of recognized national standing in the United States, selected by SCIDOSE and reasonably acceptable to EAGLE, at SCIDOSE’S expense, to have access during EAGLE’s normal business hours to such of the records of EAGLE as may be reasonably necessary to verify the accuracy of any amounts reported, actually paid or payable under this AGREEMENT for any year ending not more than twenty-four (24) months prior to the date of such request. If such accounting firm concludes that additional royalty amounts were owed to SCIDOSE during such period, EAGLE shall pay such additional royalties (including interest on such additional royalties at the rate of eight percent [*] per annum, compounded annually, or the maximum rate allowed under LAW, whichever is less from the date such royalty amounts were payable) within [*] days after the date SCIDOSE delivers to EAGLE such accounting firm’s written report so concluding. The fees charged by such accounting firm shall be paid by SCIDOSE; provided however, that if the audit discloses that the royalties payable by EAGLE for the audited period are more than [*] of the royalties actually paid for such period (excluding interest pursuant to this Section 4.2), then EAGLE shall pay the reasonable fees and expenses charged by such accounting firm.

5.3 Payment Method. EAGLE shall pay all royalties that accrue under Section 3.2 during a calendar quarter within [*] days after the end of [*]. All payments by EAGLE under this AGREEMENT shall be paid in DOLLARS, and all such payments shall be made by bank wire transfer in immediately available funds to such account as SCIDOSE shall designate in writing not less than thirty (30) days before such payment is due.

6. Confidentiality

6.1 In General. For the TERM and for a period of five (5) years thereafter, each PARTY shall maintain in confidence all information and materials of the other PARTY (including, but not limited to, KNOW-HOW and samples of the PRODUCT) disclosed or provided to it by the other PARTY (either pursuant to this AGREEMENT or the NON-DISCLOSURE AGREEMENT) and identified as confidential in writing or, if disclosed verbally or by observation, summarized in writing and submitted to RECIPIENT within thirty (30) days of the oral or visual disclosure thereof (together with all embodiments thereof, the “CONFIDENTIAL INFORMATION”). CONFIDENTIAL INFORMATION may also include information regarding intellectual property and confidential or proprietary information of THIRD PARTIES. In addition, and notwithstanding the foregoing, INVENTIONS that, under Article 9 are to be owned by one PARTY shall be

deemed CONFIDENTIAL INFORMATION of such PARTY and not the other PARTY, even if such INVENTIONS initially are generated and disclosed by the other PARTY. The terms and conditions of this AGREEMENT and the NON-DISCLOSURE AGREEMENT also shall be deemed CONFIDENTIAL INFORMATION of both PARTIES. Notwithstanding the foregoing, CONFIDENTIAL INFORMATION shall not include that portion of information or materials that the RECIPIENT can demonstrate by contemporaneous written records was (i) known to the general public at the time of its disclosure to the RECIPIENT, or thereafter became generally known to the general public, other than as a result of actions or omissions of the RECIPIENT; (ii) known by the RECIPIENT prior to the date of disclosure by the DISCLOSING PARTY; (iii) disclosed to the RECIPIENT on an unrestricted basis from a THIRD PARTY not under a duty of confidentiality to the DISCLOSING PARTY; or (iv) independently developed by the RECIPIENT by personnel that did not have access to or use of CONFIDENTIAL INFORMATION of the DISCLOSING PARTY.

Any combination of features or disclosures shall not be deemed to fall within the foregoing exclusions merely because individual features are published or known to the general public or in the rightful possession of the RECIPIENT unless the combination itself and principle of operation thereof are published or known to the general public or are in the rightful possession of the RECIPIENT.

6.2 Additional Protections. Each PARTY shall take reasonable steps to maintain the confidentiality of the CONFIDENTIAL INFORMATION of the other PARTY, which steps shall be no less protective than those that such PARTY takes to protect its own information and materials of a similar nature, but in no event less than a reasonable degree of care. Neither PARTY shall use or permit the use of any CONFIDENTIAL INFORMATION of the other PARTY except for the purposes of carrying out its obligations or exercising its rights under this AGREEMENT, and neither PARTY shall copy any CONFIDENTIAL INFORMATION of the other PARTY except as may be reasonably useful or necessary for such purposes. All CONFIDENTIAL INFORMATION of a PARTY, including all copies and derivations thereof, is and shall remain the sole and exclusive property of the DISCLOSING PARTY and subject to the restrictions provided for herein. Neither PARTY shall disclose any CONFIDENTIAL INFORMATION of the other PARTY other than to those of its directors, officers, AFFILIATES, employees, licensors, independent contractors, LICENSEES, SUBLICENSEES, assignees, agents and external advisors directly concerned with the carrying out of this AGREEMENT, on a strictly applied “need to know” basis, and provided such disclosure is subject to written confidentiality and non-use obligations no less protective than those provided herein. Other than as expressly permitted herein, RECIPIENT may not use CONFIDENTIAL

INFORMATION of the other PARTY in applying for PATENTS or securing other intellectual property rights.

6.3 Permitted Disclosures. The obligations of. Sections 6.1 and 6.2 shall not apply to the extent that RECIPIENT is required to disclose information by LAW, judicial order by a court of competent jurisdiction, or rules of a securities exchange or requirement of a governmental agency for purposes of obtaining approval to test or market the PRODUCT, or discloses information to a patent office for the purposes of filing a PATENT as permitted in this AGREEMENT; provided that the RECIPIENT shall provide prior written notice thereof to the DISCLOSING PARTY and sufficient opportunity for the DISCLOSING PARTY to review and comment on such required disclosure and request confidential treatment thereof or a protective order therefor. Notwithstanding the foregoing, either PARTY may disclose the terms and conditions of this AGREEMENT and the NONDISCLOSURE AGREEMENT to actual or potential acquirers, investors and lenders and their respective representatives under written confidentiality agreements at least as protective of the DISCLOSING PARTY’S rights as the terms and conditions of this Article 5.

6.4 Irreparable Injury. The PARTIES acknowledge that either PARTY’S breach of this Article 5 would cause the other PARTY irreparable injury for which it would not have an adequate remedy at LAW. In the event of a breach, the nonbreaching PARTY shall be entitled to injunctive relief in addition to any other remedies it may have at LAW or in equity, without necessity of posting a bond.

6.5 Return of CONFIDENTIAL INFORMATION. Each PARTY shall return or destroy all CONFIDENTIAL INFORMATION of the other PARTY in its possession upon termination or expiration of this AGREEMENT, except any CONFIDENTIAL INFORMATION that a PARTY is required by law to retain or that is necessary to allow such PARTY to perform or enjoy any of its rights or obligations that expressly survive the termination or expiration of this AGREEMENT.

7. Regulatory Matters

7.1 In General. Each PARTY has conducted and shall conduct its activities in connection with the PRODUCTS in accordance with the practices of a reasonable industry expert and in material compliance with all LAWS and, except as specifically provided in this AGREEMENT, shall bear all its own costs of doing so. Each PARTY shall promptly notify the other in writing of any information that comes to its attention concerning the safety or efficacy of the PRODUCTS, including, without limitation, any threatened or pending action by any regulatory authority with respect thereto.

7.2 Complaints and Communications. EAGLE shall be responsible for handling all complaints and communications (including with regulatory authorities) relating to the PRODUCTS in the TERRITORY.

7.3 Adverse Reaction Reporting. EAGLE shall be responsible for handling all adverse event reporting (including with regulatory authorities) relating to the PRODUCT in the TERRITORY.

7.4 PRODUCT Recalls. In the event that a PRODUCT is recalled from the market for any reason whatsoever, EAGLE shall be responsible for: (a) conducting all recall activities; and (b) all costs associated with any such recall, subject to any indemnification by SCIDOSE; provided, however, that notwithstanding anything to the contrary contained in this Agreement, any such costs shall be deducted from Net Sales and retained by EAGLE, prior to the computation of GROSS PROFIT of any PRODUCT. The PARTIES shall keep the other fully informed in writing of any notification or other information, whether received directly or indirectly, that might (i) affect the marketability, safety or effectiveness of any Product, (ii) result in liability issues or otherwise necessitate action on the part of either party or (iii) result in recall or seizure of any Product.

7.5 Ownership of 505(b)(2) Filing. The 505(b)(2) or ANDA filing (or other MARKETING AUTHORIZATION) contemplated herein shall be owned by and in the name of EAGLE, including all information and data contained therein or used to support such filing.

8. Representations, Warranties; Covenants; Limitation of Liability

8.1 By Both PARTIES. Each PARTY represents and warrants to the other that as of the EFFECTIVE DATE: (a) it has the full corporate power to enter into and perform this AGREEMENT; (b) this AGREEMENT constitutes its legal, valid and binding obligation; (c) neither it nor any of its contractors is debarred, or is in the process of being debarred, under the Generic Drug Enforcement Act of 1992, 21 U.S.C. §335; (d) each of such PARTY’S employees, officers, contractors and consultants has executed an agreement that requires such employee, officer, contractor or consultant, to the extent permitted by LAW, to assign all INVENTIONS, PATENTS, and KNOW-HOW made by or on behalf of such PARTY during the course of and as a result of the performance of such PARTY’S obligations under this AGREEMENT, to such PARTY; and (e) each of such PARTY’S employees, officers, contractors and consultants is subject to an executed agreement that requires such employee, officer, contractor or consultant to maintain as confidential any information CONTROLLED by such PARTY, or provided by the other PARTY, that is CONFIDENTIAL INFORMATION under this AGREEMENT.

8.2 By EAGLE; Diligence.

8.2.1 EAGLE covenants to SCIDOSE that, conditioned upon SCIDOSE’s fulfillment of its obligations under this Agreement, upon and after the EFFECTIVE DATE, EAGLE shall use reasonable commercial efforts to (i) develop the PRODUCTS and file for MARKETING AUTHORIZATION for the PRODUCTS in the TERRITORY as quickly as practicable after the successful completion of all stability testing and data required for such MARKETING AUTHORIZATION, including completion of all stability procedures, (ii) obtain approval of the MARKETING AUTHORIZATION for the PRODUCTS in the TERRITORY, and (iii) upon receipt of MARKETING AUTHORIZATION of a PRODUCT, use reasonable commercial efforts to commercialize and market such PRODUCT; provided, however, that Eagle shall have no obligation to hire a hospital sales force for the marketing and selling of Argatroban or [*].

8.2.2 The PARTIES acknowledge and agree that the DEVELOPMENT COMMITTEE shall, prior to MARKETING AUTHORIZATION for Argatroban or [*] (or any 505(b)(2) REPLACEMENT PRODUCT), formulate an expected business plan (which shall include a detailed budget). If at any time EAGLE’s GROSS PROFIT MARGIN for such PRODUCTS for two consecutive fiscal quarters is less than, or reasonably expected to be less than the gross margin set forth in such business plan by an amount equal to or greater than [*], then EAGLE shall have no obligation to continue to commercialize or market such PRODUCT.

8.2.3 If at any time EAGLE’s GROSS PROFIT MARGIN for the THIRD AND FOURTH PRODUCT (or applicable strength thereof or any REPLACEMENT PRODUCT related thereto) for two consecutive fiscal quarters is less than, or reasonably expected to be less than, [*], then EAGLE shall have no obligation to continue to commercialize or market such PRODUCT.

8.2.4 If the marketing of a PRODUCT is discontinued pursuant to Section 8.2.2 or 8.2.3, the PARTIES shall use their commercially reasonable efforts to sell such PRODUCT to a THIRD PARTY. If the PARTIES are unable to sell such PRODUCT to a THIRD PARTY within one hundred twenty (120) days, then SCIDOSE shall also have the right to require EAGLE, at SCIDOSE’S sole election and cost, to use reasonable efforts to provide SCIDOSE, to the extent permitted by applicable LAW, with access to and use of the 505(b)(2) filing (or other MARKETING AUTHORIZATION) and shall grant to SCIDOSE, WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, a perpetual, irrevocable, royalty-free, non-exclusive license, with the right to sublicense, to such PRODUCT, the SCIDOSE LICENSED TECHNOLOGY, the ASSIGNED

PATENTS, EAGLE PATENT RIGHTS and EAGLE KNOW-HOW solely to the extent necessary to manufacture, or have manufactured solely for sale in the TERRITORY and to develop, register, and sell such PRODUCT solely in the TERRITORY. In the event that any such license is granted, SCIDOSE shall pay royalties to EAGLE on the sale of such PRODUCT in the TERRITORY, according to the provisions of Articles 3 and 4, applied mutatis mutandi. As between the PARTIES, EAGLE shall be responsible for all development activities, and for the preparation, filing and maintenance of applications for MARKETING AUTHORIZATION for the finished PRODUCT in the TERRITORY.

8.2.5 In the event that EAGLE materially fails to perform its obligations under Section 8.2.1 in respect of any PRODUCT and fails to cure such default within sixty (60) days after SCIDOSE’s written notice thereof detailing such default (a “DEFAULT”), SCIDOSE shall have the right to require EAGLE, at SCIDOSE’S sole election and cost, on a PRODUCT-by-PRODUCT basis, to use reasonable efforts to provide SCIDOSE, to the extent permitted by applicable LAW, with access to and use of the 505(b)(2) filing (or other MARKETING AUTHORIZATIONS) in which such DEFAULT occurred, and shall grant to SCIDOSE, WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, a perpetual, irrevocable, royalty-free, non-exclusive license, with the right to sublicense, to the PRODUCT, the ASSIGNED PATENTS, the SCIDOSE LICENSED TECHNOLOGY, the EAGLE PATENT RIGHTS and the EAGLE KNOW-HOW solely to the extent necessary to manufacture, or have manufactured solely for sale in such country and to develop, register, and sell the PRODUCTS the TERRITORY. In the event that any such license is granted, SCIDOSE shall pay royalties to EAGLE on the sale of such PRODUCT in the TERRITORY, according to the provisions of Articles 3 and 4, applied mutatis mutandi.

8.3 By SCIDOSE. SCIDOSE represents and warrants to EAGLE that (a) SCIDOSE owns all right, title and interest in the ASSIGNED PATENTS and CONTROL over the LICENSED TECHNOLOGY, (b) the formulation for, manufacture, use, import, offer for sale and sale of the PRODUCT, as described in the PATENT APPLICATIONS set forth in Schedule I, does not and will not infringe or misappropriate the intellectual property rights of any THIRD PARTY, (c) EAGLE’s exercise of the license to the SCIDOSE LICENSED TECHNOLOGY granted herein will not infringe or misappropriate the intellectual property rights of any THIRD PARTY, (d) SCIDOSE and its employees and contractors complied with, and shall comply with, all LAWS in developing the formulation and manufacturing methods and processes for the PRODUCTS, and (e) neither SCIDOSE nor any of its employees or contractors violated, or will violate, any

terms of confidentiality or non-compete agreements in developing any of the PRODUCT technology methods, processes or formulations.

8.4 Non-Compete. During the Term, SCIDOSE shall not, directly or indirectly, and shall cause its Affiliates to not, directly or indirectly, (i) develop or perform any formulation or any developmental or other work or studies on or with respect to any PRODUCT for its own use or benefit in the Territory or for the use or benefit of any PERSON in the TERRITORY, or provide any PERSON with access to any intellectual property for the development of parenteral formulations of Argatroban or [*] (or, following the determination of the THIRD AND FOURTH PRODUCTS, any formulation work in respect thereof or, as applicable any REPLACEMENT PRODUCT) in any strength; (ii) manufacture for, or supply to, any PERSON any parenteral formulations of Argatroban or [*] (or, following the determination of the THIRD AND FOURTH PRODUCTS, any formulation work in respect thereof or, as applicable any REPLACEMENT PRODUCT), in any strength, for sale anywhere in the TERRITORY; or (iii) sell or distribute any parenteral formulations of Argatroban or [*] (or, following the determination of the THIRD AND FOURTH PRODUCTS, any formulation work in respect thereof or, as applicable any REPLACEMENT PRODUCT), in any strength, anywhere in the TERRITORY.

8.5 Limitation of Liability and Exclusion of Damages.

8.5.1 EXCEPT IN THE CASE OF (A) A BREACH OF ARTICLE 5, (B) THIRD PARTY CLAIMS AND (C) CLAIMS REGARDING INFRINGEMENT (THE LIMITATIONS OF WHICH ARE GOVERNED BY SECTIONS 8.5.2 AND 8.5.3 BELOW, WITHOUT LIMITING THE PARTIES’ OBLIGATIONS UNDER ARTICLE 8, IN NO EVENT SHALL SCIDOSE’S LIABILITY TO EAGLE ARISING OUT OF THIS AGREEMENT EXCEED [*] OF THE ROYALTIES PAID TO SCIDOSE BY EAGLE IN ANY CALENDAR YEAR.

8.5.2 WITH RESPECT TO INFRINGEMENT CLAIMS OTHER THAN “AT-RISK” (AS DEFINED IN SECTION 8.5.3 BELOW), THE LIMITATION PROVIDED IN SECTION 8.5.1 SHALL NOT APPLY; PROVIDED, HOWEVER, THAT (A) IN NO EVENT IN ANY CALENDAR YEAR SHALL SCIDOSE BE OBLIGATED TO MAKE PAYMENTS IN SATISFACTION OF ITS OBLIGATIONS PROVIDED IN SECTION 11.1.3 THAT EXCEED [*] OF THE ROYALTIES PAID TO SCIDOSE BY EAGLE IN SUCH CALENDAR YEAR AND (B) IN NO EVENT SHALL SCIDOSE’S LIABILITY IN RESPECT OF SUCH CLAIMS EXCEED A MAXIMUM AMOUNT EQUAL TO THE TOTAL AMOUNT RECEIVED BY SCIDOSE UNDER THIS AGREEMENT INCLUDING, FOR THE AVOIDANCE OF DOUBT, ALL MILESTONE PAYMENTS AND ROYALTY PAYMENTS.

8.5.3 In the event the parties’ elect to launch a PRODUCT “at-risk” (i.e., to commence selling a PRODUCT where prior to the first commercial sale of the PRODUCT there is a claim that the PRODUCT infringes upon third party patent rights and the patent litigation regarding such claim has not been concluded), SCIDOSE agrees that [*] of all royalties paid by EAGLE with respect to such PRODUCT shall be placed in escrow pending resolution of the claim of infringement. In the event it is determined that the PRODUCT does infringe upon a THIRD PARTY patent, the amounts held in escrow shall be applied towards payment required as a result of such determination and, as required, SCIDOSE shall be liable for up to [*] of all royalties paid by EAGLE with respect to such PRODUCT. In the event it is determined that the PRODUCT does not infringe upon a THIRD PARTY patent, such escrowed funds shall be released to SCIDOSE.

8.5.4 EXCEPT IN THE CASE OF (A) A BREACH OF ARTICLE 5, (B) THIRD PARTY CLAIMS AND (C) CLAIMS REGARDING INFRINGEMENT, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES (INCLUDING WITHOUT LIMITATION, DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS, INTERRUPTION OR LOSS OF BUSINESS OR OTHER ECONOMIC LOSS) ARISING OUT OF THIS AGREEMENT OR WITH RESPECT TO A PARTY’S PERFORMANCE OR NON-PERFORMANCE HEREUNDER EVEN IF ADVISED OF THE POSSIBILITY THEREOF.

The limitation on liability and exclusion of damages under this Section 8.5: (i) apply even if a PARTY had or should have had knowledge, actual or constructive, of the possibility of such damages; (ii) are a fundamental element of the basis of the bargain between the PARTIES and this AGREEMENT would not be entered into without such limitations and exclusions and (iii) shall apply whether a claim is based on breach of contract, breach of warranty, tort (including negligence), product liability, strict liability or otherwise, and notwithstanding any failure of essential purpose of any limited remedy herein. Moreover, the remedies under this AGREEMENT are intended to be exclusive, and the limitation on liability and exclusion of damages under this Section 8.5 are intended to apply even if there is a total and fundamental breach of this AGREEMENT, and the essential purpose of these provisions is to limit the PARTIES’ respective liabilities hereunder.

9. Indemnification; Insurance

9.1 Indemnity.

9.1.1 By SCIDOSE. Subject to the limitations set forth in Article 9, SCIDOSE shall defend, indemnify and hold EAGLE, EAGLE’S AFFILIATES, EAGLE’S LICENSEES, EAGLE’s SUBLICENSEES and the respective shareholders, directors, officers, employees, representatives and agents of each of the foregoing (each, a “EAGLE INDEMNITEE”) harmless from and against all losses, liabilities, damages, costs and expenses (including reasonable attorneys’ fees and costs of investigation and litigation, regardless of outcome) resulting from all claims, demands, actions and other proceedings by or on behalf of any THIRD PARTY (including any governmental authority) (collectively, “CLAIMS”) to the extent arising from: (a) the breach of any representation, warranty, covenant or material obligation of SCIDOSE under this AGREEMENT; or (b) the negligence, recklessness or willful misconduct of SCIDOSE in the performance of its obligations under this AGREEMENT, except in each case to the extent such claim, demand, action or proceeding arises from EAGLE’S material breach of this AGREEMENT or the negligence, recklessness or willful misconduct of a EAGLE INDEMNITEE.

9.1.2 By EAGLE. EAGLE shall defend, indemnify and hold SCIDOSE, SCIDOSE’S AFFILIATES, and the respective shareholders, directors, officers, employees and agents of each of the foregoing (each, a “SCIDOSE INDEMNITEE”) harmless from and against all losses, liabilities, damages, costs and expenses (including reasonable attorneys’ fees and costs of investigation and litigation, regardless of outcome) resulting from all CLAIMS to the extent arising from: (a) the breach of any representation, warranty, covenant or material obligation of EAGLE under this AGREEMENT; or (b) the negligence, recklessness or willful misconduct of EAGLE or its LICENSEES or any of their respective THIRD PARTY agents or subcontractors in the performance of its or their obligations under this AGREEMENT, except in each case to the extent such claim, demand, action or proceeding arises from SCIDOSE’S material breach of this AGREEMENT or the negligence, recklessness or willful misconduct of a SCIDOSE INDEMNITEE.

9.2 Insurance. EAGLE, at its own expense, shall maintain comprehensive general liability insurance, excluding product liability insurance, in the minimum amount of [*] per occurrence and in the aggregate and shall maintain product liability insurance in the minimum amount of [*] per occurrence and [*] in the aggregate. Such policies shall include a provision that SCIDOSE shall be given thirty (30) days written notice prior to cancellation or material change, including non-payment, in such a policy. The insurance carriers must be rated A-, VII or better by A.M. Best Company. EAGLE shall maintain such insurance for the TERM, and shall from time to time provide copies of certificates of such insurance to SCIDOSE upon its request. If the insurance policy is written on a claims-made

basis then the coverage must be kept in place for at least three (3) years after the termination of this AGREEMENT.

SCIDOSE, at its own expense, shall maintain comprehensive general liability insurance, in the initial minimum amount of [*] per occurrence and [*] in the aggregate, along with general umbrella insurance in the additional amount of at least [*], and thereafter in such amounts as the shall be reasonably determined by the parties. Such policies shall include a provision that EAGLE shall be given thirty (30) days written notice prior to cancellation or material change, including non-payment, in such a policy. The insurance carriers must be rated A-, VII or better by A.M. Best Company. SCIDOSE shall maintain such insurance for the TERM, and shall from time to time provide copies of certificates of such insurance to EAGLE upon its request. If the insurance policy is written on a claims-made basis then the coverage must be kept in place for at least three (3) years after the termination of this AGREEMENT.

9.3 Procedures. If any CLAIM covered by Section 9.1 is brought: (i) the indemnified PARTY shall promptly notify the indemnifying PARTY in writing of such CLAIM, (ii) the indemnifying PARTY shall assume, at its cost and expense, the sole defense of such CLAIM through counsel selected by the indemnifying PARTY and reasonably acceptable to the other PARTY, except that those indemnified may at their option and expense select and be represented by separate counsel and if they so participate, (iii) the indemnifying PARTY and those indemnified shall cooperate with one another in such defense; (iv) the indemnifying PARTY shall maintain control of such defense, except that the indemnifying PARTY may settle a CLAIM as to one indemnified only with the consent of such person or entity, not to be unreasonably withheld; (v) the indemnifying PARTY will have authority to consent to the entry of any judgment, to enter into any settlement or otherwise to dispose of such CLAIM, provided that the indemnifying PARTY obtains the prior written consent of those indemnified, not to be unreasonably withheld; and (vi) the indemnifying PARTY shall pay the full amount of any judgment, award or settlement with respect to such CLAIM and all other costs, fees and expenses that have been incurred or agreed, as the case may be, by the indemnifying PARTY in its defense or settlement of the CLAIM. In the event that the indemnifying PARTY fails to promptly assume defense of any such CLAIM, or to continue to vigorously defend such CLAIM, the indemnified PARTY, in its sole discretion, may take control of the action at the indemnifying PARTY’S expense.

10. INVENTIONS, KNOW-HOW and PATENTS

10.1 Existing Intellectual Property. Other than as expressly provided in this AGREEMENT, neither PARTY grants nor shall be deemed to grant any right, title or interest to the other PARTY in any PATENT, PATENT APPLICATION,

KNOW-HOW or other intellectual property right owned or CONTROLLED by such PARTY.

10.2 Disclosure. Each PARTY shall promptly disclose to the other in writing all INVENTIONS arising from separate activities relating to improvements to the PRODUCT and all INVENTIONS arising from joint activities (including any INVENTIONS first made, conceived or first reduced to practice as a result of such activities), or those of its agents or independent contractors, in connection with the performance of its obligations or activities under this AGREEMENT.

10.3 Ownership of INVENTIONS. Except for INVENTIONS that fall within the definition of ASSIGNED PATENTS and are therefore owned by EAGLE pursuant to Section 2.1, (a) all INVENTIONS made solely by employees, agents or independent contractors of a PARTY during the performance of this AGREEMENT (each, a “SOLE INVENTION”) shall be the exclusive property of such PARTY, and (b) if employees, agents or independent contractors of each of SCIDOSE and EAGLE jointly develop any INVENTION during the performance of activities conducted in connection with this AGREEMENT (each, a “JOINT INVENTION”), EAGLE and SCIDOSE shall each own an undivided one-half(%) interest in and to such JOINT INVENTION, and shall have the right to freely exploit and grant licenses under any such JOINT INVENTION and any PATENT claiming such JOINT INVENTION without consent of or a duty of accounting to the other PARTY. For the avoidance of doubt, the determination as to whether an INVENTION has been “solely” or “jointly” made shall be based upon whether employees, agents or independent contractors of a PARTY would be or are properly named as an inventor on a corresponding PATENT APPLICATION under United States inventorship LAWS.

10.4 Individual PATENT Filings. Each PARTY shall have sole discretion and right to prepare, file, prosecute, maintain and defend PATENT APPLICATIONS or PATENTS for INVENTIONS it solely owns under this AGREEMENT, and shall be responsible for related interference proceedings. Each PARTY shall confer with the other PARTY and shall give due consideration to the other PARTY’S suggestions regarding the prosecution of such PATENT APPLICATIONS, and shall copy the other PARTY on any official actions and submissions in such PATENT APPLICATIONS. Costs incurred with respect to PATENT APPLICATIONS shall be borne by the PARTY with the right to prosecute each such PATENT APPLICATION. For the avoidance of doubt, EAGLE shall have the sole discretion and right to prosecute, maintain and defend the PATENT APPLICATIONS included in the ASSIGNED TECHNOLOGY.

10.5 Joint PATENT Filings. With respect to all PATENT APPLICATIONS on JOINT INVENTIONS that are jointly owned by the PARTIES (the “JOINT PATENT APPLICATIONS”), the PARTIES shall determine which PARTY shall be responsible for filing, prosecuting and maintaining PATENT APPLICATIONS

and PATENTS on behalf of both PARTIES (the “RESPONSIBLE PARTY”) based on a good faith determination of the relative contributions of the PARTIES to the INVENTION and the relative interests of the PARTIES in the INVENTION. At least twenty (20) days prior to the contemplated filing of such PATENT APPLICATION, the RESPONSIBLE PARTY shall submit a substantially completed draft of the JOINT PATENT APPLICATION to the other PARTY for its approval, which shall not be unreasonably withheld or delayed. Except as set forth below, the PARTIES shall share equally the costs of the preparation, filing, prosecution and maintenance of all JOINT PATENT APPLICATIONS. If either PARTY elects not to pay its portion of any shared costs for a JOINT PATENT APPLICATION or PATENT issuing therefrom, the other PARTY may proceed with such JOINT PATENT APPLICATION in its own name and at its sole expense, in which case the PARTY electing not to pay its share of costs hereby agrees to transfer and assign and shall transfer and assign its entire right, title and interest in and to such JOINT PATENT APPLICATION to the other PARTY and such INVENTION shall be treated as a SOLE INVENTION of the assignee for the purposes of Sections 10.3 and 10.4 and this Section 10.5.

10.6 Assignment. Notwithstanding anything in this Article 10 to the contrary, nothing herein shall modify or interfere with the assignment to EAGLE of the ASSIGNED PATENTS pursuant to Section 2.1.

10.7 Further Actions. Each PARTY shall cooperate with the other PARTY to execute all documents and take all reasonable actions to effect the intent of this Article 9.

11. Infringement

11.1 Infringement of THIRD PARTY Rights.

11.1.1 Notice. If the development, manufacture, use, import or sale of the PRODUCT results in a claim for PATENT infringement by a THIRD PARTY, the PARTY to this AGREEMENT first having notice shall promptly notify the other PARTY in writing. The notice shall set forth the facts of the claim in reasonable detail.

11.1.2 Litigation Related to the PRODUCT. EAGLE shall have the option, but not the obligation, to defend any claim that the development, manufacture, use, import or sale of any PRODUCT infringes a THIRD PARTY patent or misappropriates THIRD PARTY KNOW-HOW. SCIDOSE shall cooperate with EAGLE, at EAGLE’s request, in such defense, and shall have the right to be represented by counsel of its own choice, at SCIDOSE’S expense.

11.1.3 Liability. Notwithstanding anything contained herein to the contrary, in the event of any THIRD PARTY claims a PRODUCT infringes a THIRD PARTY patent or misappropriates THIRD PARTY KNOW-HOW or otherwise brings an action, litigation or Claim relating to a breach of Sections 8.3(b) or (c), subject to Section 8.5.2, SCIDOSE and EAGLE shall [*] of the costs and expenses of such litigation (including reasonable attorneys’ expenses and fees) and any liability for any damage award or settlement, or any such other Claim. For the avoidance of doubt, in the event EAGLE reasonably expects to incur any costs, expenses and reasonable attorney’s fees in connection with any such action or CLAIM or is required to pay any royalties, license fees or such other amounts to a THIRD PARTY in order to develop, make, have made, use, offer for sale, sell, have sold or import the Product in any country, then EAGLE shall have the right to deduct such amounts from royalty payments due to SCIDOSE under this AGREEMENT.

11.2 Infringement By THIRD PARTIES

11.2.1 Notice of Infringement. If any VALID PATENT CLAIM is infringed by a THIRD PARTY, or any KNOW HOW utilized in the manufacture, use, import or sale of the PRODUCT is misappropriated by a THIRD PARTY, the PARTY first having knowledge of such infringement or misappropriation shall promptly notify the other PARTY in writing. The notice shall set forth the facts of such infringement or misappropriation in reasonable detail.

11.2.2 Prosecution of Actions Relating to SCIDOSE LICENSED TECHNOLOGY.

(a) SCIDOSE shall have the primary right, but not the obligation, to institute, prosecute and control any action or proceeding with respect to any infringement by a THIRD PARTY of SCIDOSE LICENSED TECHNOLOGY using counsel of its own choice, at its own expense. EAGLE shall cooperate with SCIDOSE at SCIDOSE’S request and expense in the prosecution of such action or proceeding. If SCIDOSE determines that EAGLE is an indispensable PARTY to the action, EAGLE hereby consents to be joined, and SCIDOSE shall defend, indemnify and hold each EAGLE INDEMNITEE harmless from any counterclaims filed against such EAGLE INDEMNITEE (except for CLAIMS for which EAGLE has an obligation to defend, indemnify and defend SCIDOSE under Section 9.1.2). EAGLE shall have the right to be represented in that action by its own counsel and at its own expense.

(b) If SCIDOSE fails to bring an action or proceeding within a period of thirty (30) days after receiving written notice from EAGLE of such infringement or misappropriation by a THIRD PARTY, EAGLE shall have the right to bring and control any such action using counsel of its own choice, and at its own expense. If EAGLE determines that SCIDOSE is an indispensable PARTY to the action, SCIDOSE hereby consents to be joined. In such event, SCIDOSE shall have the right to be represented in such action by its own counsel at its own expense. No settlement, consent judgment or other voluntary final disposition of a suit under this Section 11.2.2 may be entered into without the joint consent of EAGLE and SCIDOSE (which consent shall not be unreasonably withheld or delayed). EAGLE shall be entitled to deduct its costs of litigation from royalty payments due under Section 3.2.

(c) Awards. If either PARTY brings an action for infringement or misappropriation by a THIRD PARTY under this Section 11.2.2, any damages or other monetary awards or payments in settlement recovered by such PARTY shall be applied first to defray the costs and expenses incurred by both PARTIES in the action. Any remainder shall be [*] by the PARTIES [*] of any amount thereafter shall be retained by the PARTY bringing the action, and the balance retained by the other PARTY.

11.2.3 Prosecution of Actions Related to the Products.

(a) Except as otherwise provided in Section 11.2.2, EAGLE shall have the primary right, but not the obligation, to institute, prosecute and control any action or proceeding with respect to infringement or misappropriation by a THIRD PARTY in the TERRITORY of any PATENT, PATENT APPLICATION or KNOW-HOW owned or CONTROLLED by EAGLE related to any PRODUCT, using counsel of its own choice, at its own expense. SCIDOSE shall cooperate with EAGLE at EAGLE’s request and expense in the prosecution of such action or proceeding. If EAGLE determines that SCIDOSE is an indispensable PARTY to the action, SCIDOSE hereby consents to be joined, and EAGLE shall defend, indemnify and hold each SCIDOSE INDEMNITEE harmless from any counterclaims filed against such SCIDOSE INDEMNITEE (except for CLAIMS for which SCIDOSE has an obligation to defend, indemnify and defend EAGLE under Section 9.1.1). In such event, SCIDOSE shall have the right to be represented in that action by its own counsel and at its own expense. EAGLE shall be

entitled to deduct its costs of litigation from royalty payments due under Section 3.2.

(b) If EAGLE fails to bring an action or proceeding within a period of thirty (30) days after receiving written notice from SCIDOSE of such infringement or misappropriation by a THIRD PARTY related to any PRODUCT, SCIDOSE shall have the right to bring and control any such action using counsel of its own choice, and at its own expense. If SCIDOSE determines that EAGLE is an indispensable PARTY to the action, EAGLE hereby consents to be joined, and SCIDOSE shall defend, indemnify and hold each EAGLE INDEMNITEE harmless from any counterclaims filed against such EAGLE INDEMNITEE. In such event, EAGLE shall have the right to be represented in such action by its own counsel at its own expense. No settlement, consent judgment or other voluntary final disposition of a suit under this Section 11.2.3 may be entered into without the joint consent of both EAGLE and SCIDOSE (which consent shall not be unreasonably withheld or delayed).

(c) Awards. If either PARTY brings an action for infringement or misappropriation by a THIRD PARTY under this Section 11.2.3, any damages or other monetary awards or payments in settlement recovered by such PARTY shall be applied first to defray the costs and expenses incurred by both PARTIES in the action. Any remainder shall be [*] by the PARTIES as [*] of any amount thereafter shall be retained by the PARTY bringing the action, and the balance retained by the other PARTY.

12. Further Responsibilities of SCIDOSE

12.1 Within ten (10) business days after the EFFECTIVE DATE, SCIDOSE shall provide EAGLE with all data generated before the EFFECTIVE DATE that relates to the formulation, process and manufacturing of the PRODUCTS and shall promptly provide to EAGLE any such additional data that is generated during the Term. All such data shall be for the exclusive use of EAGLE in the TERRITORY.

12.2 SCIDOSE shall promptly provide EAGLE with all validated analytical methods for the testing of the Argatroban and [*] PRODUCTS and Argatroban and [*] active pharmaceutical ingredient required for filing and maintenance of MARKETING AUTHORIZATIONS for the PRODUCTS in the TERRITORY.

12.3 SCIDOSE shall promptly provide EAGLE with all stability data generated on research formulations and pilot batches of the PRODUCTS. Furthermore,

SCIDOSE shall successfully complete all research stability studies and promptly provide EAGLE with all data therefrom.

12.4 SCIDOSE shall provide EAGLE with technical support as reasonably requested by EAGLE relating to the scale-up of the manufacturing process for the PRODUCTS and the manufacturing of the FDA filing lots of the PRODUCTS at EAGLE’s contract manufacturer. In addition, SCIDOSE will assist EAGLE in responding to FDA questions on the 505(b)(2) filing that relate to the manufacturing process of such PRODUCT or related analytical methods.

12.5 SCIDOSE shall promptly provide EAGLE with all information, back-up information, data and correspondence utilized in the filing of the ASSIGNED PATENTS. Furthermore, SCIDOSE shall assist EAGLE with the compilation of information for and filing of further PATENT APPLICATIONS relating to the PRODUCT in the TERRITORY. All such PATENT APPLICATIONS shall be owned by EAGLE.

12.6 SCIDOSE shall assist EAGLE in gathering toxicology information from the literature or any other scientific information required to support the 505(b)(2) filings for the Argatroban and [*] PRODUCTS.

12.7 All reasonable, out-of-pocket costs and expenses pre-approved by EAGLE, including travel expenses, incurred by SCIDOSE in the performance of its activities under this Article 12 shall be borne by EAGLE.

13. Term and Termination

13.1 Expiration. The term of this AGREEMENT (the “TERM”) shall commence on the EFFECTIVE DATE and shall expire upon the expiration of all royalty obligations, unless earlier terminated as provided herein.

13.2 Termination for Default. Each PARTY shall have the right to terminate this AGREEMENT by written notice to the other PARTY for a material failure to comply with the terms of this AGREEMENT by the other PARTY, provided such failure to comply is not corrected by the failing PARTY within [*] after written notice of any failure to make timely payment of royalties or any other amount, when due hereunder, or within [*] after receipt of written notice of any other failure from the non-failing PARTY.

13.3 Additional Termination Rights. The PARTIES hereto shall have the additional termination rights:

13.3.1 If the costs and expenses of the clinical trials for Argatroban or [*] are reasonably expected to be greater than [*], then EAGLE may terminate this Agreement with respect to such PRODUCT.

13.3.2 If either or both of the 505(b)(2) applications for Argatroban or [*] has not been accepted by the FDA on or before the date that is [*] from the EFFECTIVE DATE, then Eagle may terminate this Agreement with respect to such PRODUCT.

13.3.3 If the PARTIES reasonably determine that a generic version of [*] will enter the market prior to [*], then the PARTIES may mutually agree to terminate this Agreement in respect of [*].

13.4 Effect of Termination.

13.4.1 Except as other wise provided in Section 13.4.3 below, the provisions of Sections 2.1 (further assurances), 2.2 (license), 2.3, 2.4, 2.6 (further assurances), 3.3, 7.4, 8.5, 12.7, 13.4, 16.2, 16.4, 16.7, 16.9 and 16.10 and Articles 5, 6, 9, 10, 11, 14 and 15 (and in each case together with any defined terms applicable to such provisions) shall survive termination of this AGREEMENT for any reason whatsoever.

13.4.2 If this AGREEMENT is terminated by EAGLE pursuant to Section 13.2, then EAGLE shall have an exclusive, royalty-free, fully-paid up, perpetual license to the LICENSED TECHNOLOGY to make, sell and have sold the PRODUCTS in the TERRITORY.

13.4.3 If this AGREEMENT is terminated by SCIDOSE pursuant to Section 13.2 or 13.3, then EAGLE shall (A) transfer and assign to SCIDOSE all rights to (i) the ASSIGNED PATENTS and (ii) the MARKETING AUTHORIZATIONS to the PRODUCT and (B) automatically be deemed to have granted to SCIDOSE, WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, a perpetual, irrevocable, royalty-free, exclusive license, with the right to sublicense, to the PRODUCT, the SCIDOSE LICENSED TECHNOLOGY, the ASSIGNED PATENTS, the EAGLE PATENT RIGHTS and the EAGLE KNOW-HOW solely to the extent necessary to manufacture, or have manufactured anywhere in the world solely for sale in the TERRITORY and develop, register, and sell and have sold the PRODUCTS in the TERRITORY. If the event EAGLE fails to execute any document or instrument necessary to effectuate the foregoing, EAGLE hereby grants an irrevocable power of attorney to SCIDOSE solely for such purposes. In the event of a termination of this AGREEMENT pursuant to Section 13.2, Sections 3.3, 5.1-5.3 (but only with respect to PRODUCTS sold by EAGLE), 7.4, 8.5, 12.7, 13.4, 16.2, 16.4, 16.7, 16.9 and 16.10 and Articles 6, 9, 10, 14 and 15 (and in each case together with any defined terms applicable to such provisions) shall survive termination of this AGREEMENT.

13.4.4 If this Agreement is terminated by EAGLE pursuant to Sections 13.3.1, 13.3.2 or 13.3.3, then the license granted by SCIDOSE in respect of such PRODUCT(S) shall terminate immediately and EAGLE shall be entitled to the repayment of the paid milestone in respect of such PRODUCT(S) as if there had been a PRODUCT FAILURE.

13.4.5 If the PARTIES terminate this Agreement pursuant to Section 13.3.3, then [*] shall be deemed a PRODUCT FAILURE and subject to Sections 3.1.2 and 4.1.3, the PARTIES will use their good faith efforts to agree to a REPLACEMENT PRODUCT and the milestones will paid and to be paid will be applied to such new PRODUCT.

13.4.6 This Agreement shall automatically terminate upon the initiation of any proceeding in bankruptcy, reorganization, dissolution, liquidation or arrangement for the appointment of a receiver or trustee to take possession of the assets of a party hereto or similar proceeding under the law for release of creditors by or against a party hereto or if a party hereto shall make a general assignment for the benefit of its creditors. All licenses and rights to licenses granted under or pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code (the “Code”), licenses of rights to “intellectual property” as defined under Section 101(35A) of the Code. Either party, as a licensee of such rights under this Agreement (the “non-Bankrupt Party”), shall retain and may fully exercise all of its rights and elections under the Code, and upon commencement of a bankruptcy proceeding by or against the other party (the “Bankrupt Party”) under the Code, shall be entitled to a complete duplicate of, or complete access to (as the non-Bankrupt Party deems appropriate), any such intellectual property and all embodiments of such intellectual property. Such intellectual property and all embodiments thereof shall be promptly delivered to the non-Bankrupt Party (a) upon any such commencement of a bankruptcy proceeding upon written request therefor by the non-Bankrupt Party, unless the Bankrupt Party elects to continue to perform all of its obligations under this Agreement or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of the Bankrupt Party upon written request therefor by the non-Bankrupt Party, and each party hereby acknowledges and agrees that the foregoing shall serve as its consent to such transfer of the intellectual property and all embodiments thereof. The foregoing provisions of this Section 13.4.6 are without prejudice to any rights the non-Bankrupt Party may have arising under the Code or other applicable law.

13.4.7 Notwithstanding anything in this AGREEMENT to the contrary, if this AGREEMENT is terminated for any reason whatsoever, EAGLE shall pay SCIDOSE all accrued milestone payments and accrued royalties in accordance with the terms of this AGREEMENT.

13.4.8 Termination of this AGREEMENT by a PARTY shall not be an exclusive remedy and all other remedies will be available to the terminating PARTY, in equity and at LAW.

13.4.9 If this Agreement is terminated in respect of any Product, then this Agreement shall continue in full force and effect in respect of any other the Product.

13.4.10 The termination or expiration of this Agreement shall not affect any payment or other obligations or liabilities that have accrued prior to or on the date of such termination or expiration, and the PARTIES shall retain all rights and remedies (at law or in equity) in respect of any breach hereof.

14. Assignment

Unless otherwise expressly permitted hereunder, neither PARTY may assign any of its rights or delegate any of its duties under this AGREEMENT without the prior written consent of the other PARTY, except that either PARTY may assign its rights and responsibilities hereunder without the other PARTY’S consent as part of: (i) either (a) the sale of all or substantially all of the assets or the entire business to which this AGREEMENT relates or (b) a merger, consolidation, reorganization or other combination with or into another person or entity; or (ii) the transfer or assignment to an AFFILIATE, in each case, pursuant to which the surviving entity or assignee assumes the assigning or merging PARTY’S obligations hereunder in writing. Subject to confidentiality obligations, each PARTY shall use reasonable efforts to notify the other PARTY at least thirty (30) days in advance of any such assignment. Any assignment made in violation of this Article 14 shall be null and void. Notwithstanding the foregoing, EAGLE acknowledges that SCIDOSE intends to use TherDose Parma Limited, an Indian Private Limited company, solely to perform analytical testing for the PRODUCTS, and SCIDOSE agrees that it shall remain responsible to EAGLE for all acts and omissions of Thermoses.

15. Notices

Any notice or other communication or payment herein required or permitted to be given shall be deemed sufficient if and when personally delivered in writing or if and when given by United States registered or certified mail, postage prepaid, return receipt requested, properly addressed to the respective addresses of the PARTIES as written below. Notices so given shall be effective upon the earlier to occur of (i) receipt by the

PARTY to which notice is given, or (ii) the fourth (41 ) business day following the date such notice was posted, whichever occurs first.

If to EAGLE, addressed to:

Eagle Pharmaceutical, Inc.

000 Xxxxxxxx Xxxxx

Xxxxxxxxx Xxxx, XX 00000

Attn: Xxxxx Tariff, Chief Executive Officer

Fax: With copies (which shall not constitute notice), to:

Xxxxxx, Xxxxxxxxxx & Xxxxxxxxx LLP

000 Xxxxx Xxxxxx

Xxx Xxxx, XX 00000

Attn: X. Xxxx Milling, Jr., Esq.

Fax: (000) 000-0000

If to SCIDOSE, addressed to:

SciDose, LLC

000 Xxxxxxxxxx Xxxx

Xxxxxxx, XX 00000

Attention: Xxxxxx X. Xxxxx

President & CEO

With copies (which shall not constitute notice), to:

Xxxxx Xxxxxx Xxxxxxxx & Xxxxxx LLP

000 Xxxxxxxxx Xxxxxx, Xxxxx 0000

Xxx Xxxx, Xxx Xxxx 00000

Attention: Xxxxxxxx Xxxxxx

16. Miscellaneous

16.1 Force Majeure. Neither PARTY shall be held liable or responsible to the other PARTY nor be deemed to have defaulted under or breached this AGREEMENT for failure or delay in fulfilling or performing any term of this AGREEMENT to the extent, and for so long as, such failure or delay is caused by or results from causes beyond the reasonable control of the affected PARTY; provided, however, that the foregoing shall not be applied to excuse or delay any payment obligation of EAGLE under this AGREEMENT; provided, further, that upon cessation of such force majeure event, such PARTY shall promptly resume performance hereunder. Notwithstanding the foregoing, in the event that any force majeure event shall continue for more than ninety (90) days, the PARTY not subject to

such force majeure event may, in its sole discretion, terminate this AGREEMENT upon written notice to the other PARTY.

16.2 Severability. All the terms and provisions of this AGREEMENT are distinct and severable, and if any term or provision is held unenforceable, illegal or void in whole or in part by any court, regulatory authority or other competent authority it shall to that extent be deemed not to form part of this AGREEMENT, and the enforceability, legality and validity of the remainder of this AGREEMENT shall not be affected thereby.

16.3 Variation. This AGREEMENT may not be amended, varied or modified in any manner except by an instrument in writing signed by a duly authorized officer or representative of each PARTY hereto.

16.4 Forbearance and Waiver. No waiver by a PARTY in respect of any breach shall operate as a waiver in respect of any subsequent breach. No forbearance, failure or delay by a PARTY in exercising any right or remedy shall operate as a waiver thereof, nor shall any single or partial forbearance, exercise or waiver of any right or remedy prejudice its further exercise of any right or remedy under this AGREEMENT or at LAW.

16.5 Counterparts. This AGREEMENT may be executed in more than one counterpart, each of which constitutes an original and all of which together shall constitute one enforceable agreement.

16.6 No Partnership. The relationship of the PARTIES is that of independent contractors and this AGREEMENT shall not operate so as to create a partnership or joint venture of any kind between the PARTIES.

16.7 Construction. The PARTIES have participated jointly in the negotiation and drafting of this AGREEMENT. In the event that an ambiguity or question of intent or interpretation arises, this AGREEMENT shall be construed as if drafted jointly by the PARTIES and no presumption or burden of proof shall arise favoring or disfavoring any PARTY by virtue of the authorship of any of the provisions of this AGREEMENT. Except where the context otherwise requires, where used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). The captions of this AGREEMENT are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this AGREEMENT or the intent of any provision contained in this AGREEMENT. The term “including” as used herein means “including without limitation.”

16.8 Entire Agreement. This AGREEMENT and Schedules attached hereto constitute the entire understanding between the PARTIES and supersedes any prior or

contemporaneous written or oral understanding, negotiations or agreements between and among them respecting the subject matter hereof. This AGREEMENT shall be binding upon, and inure to the benefit of, the PARTIES and their respective successors and assigns.

16.9 Governing LAW. This AGREEMENT shall be governed by and construed in accordance with the LAWS of the State of Delaware without regard to its or any other jurisdiction’s choice of LAW rules. Any disputes under this AGREEMENT shall be brought in the state or federal courts located in New York. The PARTIES submit to the personal jurisdiction of such courts for any such action, agree that such courts provide a convenient forum for any such action, and waive any objections or challenges to venue with respect to such courts.

16.10 Publicity. Except as otherwise provided in Article 5 and subject to either PARTY’S reporting obligations under applicable state and federal (including securities) LAWS, SCIDOSE and EAGLE shall not use the other PARTY’S name in publicity materials or other public disclosures without the prior written consent of the other PARTY, such consent not to be unreasonably withheld or delayed. Notwithstanding the foregoing, SCIDOSE and EAGLE shall prepare and issue a joint press release reasonably acceptable to both PARTIES announcing the relationship created under this AGREEMENT. During the TERM, EAGLE shall inform SCIDOSE prior to issuing a press release or other public disclosure regarding the achievement of clinical or other developmental milestones for a PRODUCT. If EAGLE intends to mention in such public disclosure the use of proprietary technology in a PRODUCT as having been developed by SCIDOSE, such mention must be approved in writing by SCIDOSE (such approval not to be unreasonably withheld or delayed).

16.11 Termination of NON-DISCLOSURE AGREEMENT. All provisions of, rights granted and covenants made in the NON-DISCLOSURE AGREEMENT are hereby terminated and of no further force and effect and are superseded in their entirety by the provisions of, rights granted and covenants made in this AGREEMENT. The PARTIES acknowledge and agree that any disclosure made pursuant to the NON-DISCLOSURE AGREEMENT shall be governed by the terms and conditions of Article 5 of this AGREEMENT.

16.12 Compliance with LAWS. Each PARTY will comply with all LAWS in performing its obligations and exercising its. rights hereunder. Nothing in this AGREEMENT shall be deemed to permit EAGLE or its LICENSEES to export, re-export or otherwise transfer any information or materials transferred hereunder or PRODUCT manufactured therefrom without complying with LAWS.

[Signature Page Follows]

IN WITNESS WHEREOF, the PARTIES hereto have caused their authorized representatives to execute this AGREEMENT by signing below:

Signed:

For and on behalf of:		For and on behalf of:

SCIDOSE, LLC		EAGLE PHARMACEUTICAL, INC.


Signature	/s/ Xxxxxx X. Xxxxx	Signature	/s/ Xxxxx Xxxxxxx

Name:	Xxxxxx X. Xxxxx	Name:	Xxxxx Xxxxxxx

Title:	President & CEO	Title:	Chief Executive Officer

SCHEDULE I

PATENT APPLICATIONS

SCHEDULE II

Milestones

Pursuant to Section 3.1, the following payments shall be payable by EAGLE to SCIDOSE upon occurrence of the following milestone events with respect to each of the PRODUCTS:

Milestone Event		Milestone Payment (US DOLLARS)
Upon the execution of this AGREEMENT		[*]
On or before [*]		[*]
On or before [*]		[*]
[*]		[*]
[*]		[*]
[*]		[*]
[*]		[*]
[*]		[*]

SCHEDULE III

MILESTONES TO BE COMPLETED BY SCIDOSE

Item	Description of Activity	Timing
1	FDA acceptance of the 505(b)(2) for the Argatroban and [*] PRODUCTS	[*] months from execution of this Agreement
2	FDA acceptance of the 505(b)(2) or ANDA filings for the additional two PRODUCTS	[*] months from the transfer of technical information by SCIDOSE to EAGLE

SCHEDULE IV

Allocation of Milestones

Product	Signing Date	FDA filing Acceptance of 505(b)(2) or ANDA (as applicable)	Commercial Launch
Argatroban	[*]	[*]	[*]
[*]	[*]	[*]	[*]
Product#3	[*]	[*]	[*]
Product #4	[*]	[*]	[*]

AMENDMENT NO. 1 TO

DEVELOPMENT AND LICENSING AGREEMENT

THIS AMENDMENT NO. 1 TO THE DEVELOPMENT AND LICENSING AGREEMENT (this “Amendment”) is made as of March 18, 2008 (the “Amendment Date”), by and between Eagle Pharmaceuticals, Inc. (“EAGLE”), and SciDose LLC, (“SCIDOSE”), and amends that certain Development and Licensing Agreement dated as of June 12, 2007, (the “Original Agreement”), by and between the EAGLE and SCIDOSE. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in the Original Agreement.

WHEREAS, EAGLE and SCIDOSE desire to amend the Original Agreement, as more particularly set forth herein.

NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1. Amendment to Section 1.28 of the Original Agreement is hereby amended by deleting the entire clause thereof and replacing it with:

1.28 “NET SALES” means, with respect to any PRODUCT, the amount invoiced by (or in the absence of an invoice, the amounts payable to) EAGLE or its AFFILIATES for the sale to THIRD PARTIES of such PRODUCT less the following: (i) customary administration fees, drug wholesaler fees, charge-backs, rebates (including Medicaid, Medicare and similar rebates) and trade and customary quantity discounts actually allowed and taken, including shelf stock adjustments, cash and volume discounts, chargebacks, promotional allowances, inventory obsolescence; (ii) allowances whether paid or accrued for returned PRODUCT; (iii) documented freight, postage, shipping costs and insurance paid by EAGLE (if separately stated); (iv) government-mandated and other rebates customary in the industry; (v) value added tax, sales, use or turnover taxes, excise taxes and customs duties and (vi) if applicable, expenses related to (A) PRODUCT recalls in accordance with Section 7.4, (B) infringement litigation in accordance with Sections 11.1.3, 11.2.2(b) and/or 11.2.3(a), and (C) marketing costs (other than SALES FORCE COSTS) directly related to the PRODUCTS (or, as applicable, the REPLACEMENT PRODUCTS related thereto). NET SALES shall be deemed to accrue upon the date of the invoice for the PRODUCT. In addition, NET SALES by EAGLE hereunder are subject to the following, as accrued on EAGLE’s book in good faith:

2. Amendment to Section 1.30 of the Original Agreement is hereby amended by deleting the entire clause thereof and replacing it with:

1.30 “PRODUCT(S)” means (i) all parenteral formulations of Argatroban and [*]; (ii) [*] and (iii) BIVALIRUDIN.

3. Amendment to Section 1.35 of the Original Agreement is hereby amended by deleting the entire clause thereof and replacing it with:

1.35 “ROYALTY RATE” means, (i) with respect to Argatroban, [*] and Bivalirudin, [*]; and (ii) with respect to [*], [*].

4. Amendment to Section 1.45 of the Original Agreement is hereby amended by deleting the entire clause thereof and replacing it with:

1.45 “TERRITORY” means worldwide (excluding China) for 505(b)(2) PRODUCT applications, however, TERRITORY means only North America (including the United States, its territories and possessions and Canada) for ANDA PRODUCT applications.

5. Amendment to Section 3.1 of the Original Agreement is hereby amended by the addition of the following clauses thereof:

3.1.5 In the event EAGLE licenses PRODUCT to a THIRD PARTY, any milestone payments received by EAGLE with respect to commercialization of the PRODUCT in the US market [*] between SCIDOSE and EAGLE; however, subject to Section 3.1.4, any milestone payment received with respect to commercialization of the PRODUCT ex-US will be wholly paid to SCIDOSE.

6. Amendment to Section 11.2.3(a) of the Original Agreement is hereby amended by deleting the entire Section 11.2.3(a) thereof and replacing it with:

11.2.3(a) Except as otherwise provided in Section 11.2.2, EAGLE shall have the primary right, but not the obligation, to institute, prosecute and control any action or proceeding with respect to infringement or misappropriation by a THIRD PARTY in the TERRITORY of any PATENT, PATENT APPLICATION or KNOW-HOW owned or CONTROLLED by EAGLE related to the PRODUCT, using counsel of its own choice, at its own expense. SCIDOSE shall cooperate with EAGLE at EAGLE’s request and expense in the prosecution of such action or proceeding. If EAGLE determines that SCIDOSE is an indispensable PARTY to the action, SCIDOSE hereby consents to be joined, and EAGLE shall defend, indemnify and hold each SCIDOSE INDEMNITEE harmless from any counterclaims filed against such SCIDOSE INDEMNITEE (except for CLAIMS for which SCIDOSE has an obligation to defend, indemnify and defend EAGLE under Section 9.1.1). In such event, SCIDOSE shall have the right to be represented in that action by its own counsel and at its own expense. EAGLE shall be entitled to deduct its costs of litigation from royalty payments of any PRODUCT due under Section 3.2.

7. Amendment to Section 13.4 of the Original Agreement is hereby amended by the addition of two following clauses thereof:

13.4.10 In the event of termination by either PARTY pursuant to Section 13.1, 13.2, EAGLE shall have the right, but not the obligation, to sell off any inventory on hand or in transit to EAGLE. For any PRODUCT sales, EAGLE will appropriately pay SCIDOSE its ROYALTY RATE.

13.4.11 In the event SCIDOSE terminates the Agreement pursuant to Section 13.1, 13.2, EAGLE shall have the right to cancel any purchase orders placed, which have not yet shipped.

8. Effect on the Original Agreement. Except as specifically amended herein, the Original Agreement, all other documents, instruments and agreements executed and/or delivered in connection therewith, shall remain in full force and effect, and are hereby ratified and confirmed. As of the Amendment Date, each reference in the Original Agreement to “this Agreement,” “hereunder,” “hereof,” “herein” or words of like import shall mean and be a reference to the Original Agreement as amended hereby.

9. Entire Agreement. The Original Agreement, as modified by this Amendment, and the other writings specifically identified therein and herein or contemplated thereby and hereby, is complete, reflects the entire agreement of the Parties with respect to the subject matter hereof, and supersedes all previous written or oral negotiations, commitments and writings.

[The remainder of this page has been intentionally left blank]

IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed and delivered by their respective proper and duly authorized representatives as of the date first set forth above.

EAGLE PHARMACEUTICALS, INC.


By:	/s/ Xxxxx Xxxxxxx
	Name:	Xxxxx Xxxxxxx
	Title:	President and CEO


SCIDOSE, LLC


By:	/s/ Xxxxxx Xxxxx
	Name:	Xxxxxx Xxxxx
	Title:	President and CEO

AMENDMENT NO. 2 TO

DEVELOPMENT AND LICENSING AGREEMENT

THIS AMENDMENT NO. 2 TO THE DEVELOPMENT AND LICENSING AGREEMENT (this “Amendment”) is made as of March 25, 2008 (the “Amendment Date”), by and between Eagle Pharmaceuticals, Inc. (“EAGLE”), and SciDose LLC, (“SCIDOSE”), and amends that certain Development and Licensing Agreement dated as of June 12, 2007, which was subsequently amended on March 18, 2008, (the “Original Agreement”), by and between the EAGLE and SCIDOSE. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in the Original Agreement.

WHEREAS, EAGLE and SCIDOSE desire to amend the Original Agreement, as more particularly set forth herein.

1. Amendment to Section 1.45 of the Original Agreement is hereby amended to read in its entirety as it appears in this Amendment:

1.45 “TERRITORY” means the following:

(i) Worldwide (excluding China) for [*] and Argatroban.

(ii) Worldwide for Bivalirudin.

(iii) North America (including the United States, its territories and possessions and Canada) for [*].

2. Amendment to Section 3.2 of the Original Agreement is hereby amended by the addition of the following sentence at the end of the clause:

“In the event EAGLE licenses the Bivalirudin PRODUCT to a THIRD PARTY for marketing in China, any Royalties received by EAGLE from such THIRD PARTY license will be [*] to SCIDOSE.”

3. Effect on the Original Agreement. Except as specifically amended herein, the Original Agreement, all other documents, instruments and agreements executed and/or delivered in connection therewith, shall remain in full force and effect, and are hereby ratified and confirmed. As of the Amendment Date, each reference in the Original Agreement to “this Agreement,” “hereunder,” “hereof,” “herein” or words of like import shall mean and be a reference to the Original Agreement as amended hereby.

4. Entire Agreement. The Original Agreement, as modified by this Amendment, and the other writings specifically identified therein and herein or contemplated thereby and hereby,

is complete, reflects the entire agreement of the Parties with respect to the subject matter hereof, and supersedes all previous written or oral negotiations, commitments and writings.

IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed and delivered by their respective proper and duly authorized representatives as of the date first set forth above.

EAGLE PHARMACEUTICALS, INC.


By:	/s/ Xxxxx Xxxxxxx
	Name:	Xxxxx Xxxxxxx
	Title:	President and CEO


SCIDOSE, LLC


By:	/s/ Xxxxxx Xxxxx
	Name:	Xxxxxx Xxxxx
	Title:	President and CEO

AMENDMENT NO. 3 TO

DEVELOPMENT AND LICENSING AGREEMENT

THIS AMENDMENT NO. 3 TO THE DEVELOPMENT AND LICENSING AGREEMENT (this “3rd Amendment”) is made as of December 3rd, 2008 (the “Amendment Date”), by and between Eagle Pharmaceuticals, Inc. (“EAGLE”), and SciDose LLC, (“SCIDOSE”), and amends that certain Development and Licensing Agreement dated as of June 12, 2007, as amended (the “Original Agreement”), by and between the EAGLE and SCIDOSE. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in the Original Agreement.

WHEREAS, EAGLE and SCIDOSE desire to amend the Original Agreement, as more particularly set forth herein.

1. Amendment to Section 1.30 of the Original Agreement is hereby amended by deleting the entire clause thereof and replacing it with:

1.30 “PRODUCT(S)” means (i) all parenteral formulations of Argatroban, (ii) all parenteral formulations of Bivalirudin, which, from and after the Amendment Date, shall replace any reference to [*] when used in the Original Agreement, (iii) all parenteral formulations of [*], which, from and after the Amendment Date, shall be deemed the THIRD PRODUCT and (iv) [*] which, from and after the Amendment Date, shall be deemed the FOURTH PRODUCT, and together with the THIRD PRODUCT, the THIRD AND FOURTH PRODUCTS.

2. Amendment to Section 1.35 of the Original Agreement is hereby amended by deleting the entire clause thereof and replacing it with:

1.35 “ROYALTY RATE” means (i) with respect to any PRODUCT that is subject to a 505(b)(2) application, [*], and (ii) with respect to any PRODUCT that is subject to an ANDA application, [*].

3. Amendment to Section 1.45 of the Original Agreement is hereby amended by deleting the entire clause thereof and replacing it with:

1.45 “TERRITORY” means the following:

(i) Worldwide (excluding China) for Argatroban, [*] and [*]

(ii) Worldwide for Bivalirudin.

4. Amendment to Section 1.46 of the Original Agreement is hereby amended by deleting the entire clause thereof and replacing it with:

1.45 “THIRD AND FOURTH PRODUCTS” has the meaning, subject to Section 2.7 of the Original Agreement, set forth in the Amendment to Section 1.30 in the first paragraph of this 3rd Amendment.

5. Amendment to Section 3.1.1 of the Original Agreement is hereby amended by deleting the entire Section 3.1.1 thereof and replacing it with:

EAGLE shall pay to SCIDOSE the respective milestone payments in accordance with and on the respective dates provided in Schedule II hereto. Such milestone payments shall be in addition to any royalty or other payments due under this AGREEMENT and are allocated among the PRODUCTS as follows:

Argatroban		[*]
Bivalirudin		[*]
THIRD PRODUCT		[*]
FOURTH PRODUCT		[*]

6. Amendment to Schedule III of the Original Agreement is hereby amended by deleting the entire schedule thereof and replacing it with:

SCHEDULE III

MILESTONES TO BE COMPLETED BY SCIDOSE

Item	Description of Activity	Timing
1	FDA acceptance of the 505(b)(2) for the Argatroban PRODUCT	[*] months from execution of the Original Agreement

2	FDA acceptance of the 505(b)(2) for the Bivalirudin PRODUCT	[ ]

3	FDA acceptance of the 505(b)(2) or ANDA filings for the THIRD AND FOURTH PRODUCTS	[ ]

7. Effect on the Original Agreement. Except as specifically amended herein, the Original Agreement, all other documents, instruments and agreements executed and/or delivered in connection therewith, shall remain in full force and effect, and are hereby ratified and confirmed. As of the Amendment Date, each reference in the Original Agreement to “this Agreement,” “hereunder,” “hereof,” “herein” or words of like import shall mean and be a reference to the Original Agreement as amended hereby.

8. Entire Agreement. The Original Agreement, as modified by this 3rd Amendment, and the other writings specifically identified therein and herein or contemplated thereby and hereby, is complete, reflects the entire agreement of the Parties with respect to the subject matter hereof, and supersedes all previous written or oral negotiations, commitments and writings.

[The remainder of this page has been intentionally left blank]

IN WITNESS WHEREOF, the Parties have caused this 3rd Amendment to be executed and delivered by their respective proper and duly authorized representatives as of the date first set forth above.

EAGLE PHARMACEUTICALS, INC.


By:	/s/ Xxxxx Tariff
	Name:	Xxxxx Xxxxxxx
	Title:	President and CEO


SCIDOSE, LLC


By:	/s/ Xxxxxx Xxxxx
	Name:	Xxxxxx Xxxxx
	Title:	President and CEO

EXECUTION VERSION

AGREEMENT

THIS AGREEMENT (this “Agreement”) is made as of July 16, 2013 by and between Eagle Pharmaceuticals, Inc. (“EAGLE”), SciDose LLC(“SCIDOSE”), Xxxxxx One (“XXXXXX”) and Therdose, LLC (“THERDOSE”; and, collectively with SCIDOSE AND XXXXXX, the “SCIDOSE PARTIES”).

WHEREAS, EAGLE and the SCIDOSE”PARTIES have entered into various agreements listed on Exhibit A, including amendments thereto and side letters in respect thereof (collectively, the “DEVELOPMENT AGREEMENTS”);

WHEREAS, EAGLE and XXXXXX desire to amend the DEVELOPMENT AGREEMENTS and have reached other agreements in respect thereof, as more particularly set forth herein.

NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1. Amendments to the 2008 Eagle/Xxxxxx Agreement.

(a) Amendment to Section 1. Section 1 of that certain Development and License Agreement dated as of March 18, 2008, as amended (the “2008 Eagle/Xxxxxx Agreement”), by and between the EAGLE and XXXXXX is hereby amended by adding the following new definition as a new Section 1.41:

“1.41 “BENDAMUSTINE PRODUCTS” means, together, the Bendamustine parenteral formulation product (i.e., the RTU Bendamustine product licensed hereunder) and EAGLE [*] Bendamustine product.”.

(b) Amendment to Section 1.32. The first sentence of Section1.32 of the 2008 Eagle/Xxxxxx Agreement is hereby amended by deleting such sentence only and replacing it with:

“1.32 “PRODUCT(S)” means five (5) ANDA or 505(b)(2) products as set forth in Exhibit A, and will expressly include the BENDAMUSTINE PRODUCTS.”

(c) Amendment to Section 1.37. Section 1.37 of the 2008 Eagle/Xxxxxx Agreement is hereby amended by deleting such Section in its entirety and replacing it with the following:

“1.37 “ROYALTY RATE” means (i) with respect to any PRODUCT that is subject to a 505(b)(2) application, [*] and (ii) with respect to any PRODUCT that is subject to an ANDA application, [*]; provided, however, that, with respect to the BENDAMUSTINE PRODUCTS, the ROYALTY RATE means [*].”

(d) Amendment to Section 3.2. Section 3.2 of the 2008 Eagle/Xxxxxx Agreement is hereby amended by deleting such Section its entirety and replacing it with the following:

“For the applicable ROYALTY TERM for each PRODUCT, EAGLE shall pay XXXXXX royalties on sales of PRODUCTS by EAGLE and its AFFlLIATES in the TERRITORY in an amount equal to the ROYALTY RATE multiplied by the GROSS PROFIT from the number of units of PRODUCTS sold; provided, however, that, (i) at any time during [*] after the FIRST COMMERCIAL SALE of a PRODUCT, there is no VALID PATENT CLAIM covering the manufacture, use, import or sale of such PRODUCT in a country in the Territory, then (i) with respect to a PRODUCT (or any REPLACEMENT PRODUCT, as applicable) other than the BENDAMUSTINE PRODUCTS, the ROYALTY RATE shall be reduced to [*] in such country. Notwithstanding the foregoing, EAGLE shall no longer have an obligation to pay royalties to XXXXXX or any of’ its AFFILIATES in respect of the sales of BENDAMUSTINE PRODUCTS after EAGLE has paid royalties to XXXXXX in an amount equal to [*] from the sales of BENDAMUSTINE PRODUCTS (the “ROYALTY CAP”) and, after EAGLE shall have paid the ROYALTY CAP, the license in respect of the BENDAMUSTINE PRODUCTS shall be [*].”

(e) Amendment to Section 8.4. Section 8.4 of the 2008 Eagle/Xxxxxx Agreement is hereby amended by adding the following sentence:

‘‘Notwithstanding the foregoing, XXXXXX and any of its AFFILIATES shall be entitled to develop, manufacture and Commercialize ANDA formulations for its own account in respect of [*].”

(f) Effect on the 2008 Eagle/Xxxxxx Agreement. Except as specifically amended herein, the 2008 Eagle/Xxxxxx Agreement, al1 other documents, instruments and agreements executed and/or delivered in connection then with, shall remain in full force and effect, and are hereby ratified and confirmed.

2. Amendments to the 2009 Eagle/Xxxxxx Agreement. On December 23, 2010, the XXXXXX and EAGLE amended the February 13, 2009 License and Development Agreement (the “2009 Eagle/Xxxxxx Agreement”) to include [*] and [*] as PRODUCTS. The parties hereto

agree that such amendment, in respect of such products only, is hereby terminated and of no force and effect and that EAGLE shall have no rights, and XXXXXX shall have no obligations, in respect of such products under the 2009 Eagle/Xxxxxx Agreement or otherwise. For the avoidance of doubt, except as set forth in this Section 2, the 2009 Eagle/Xxxxxx Agreement, all other documents, instruments and agreements executed and/or delivered in connection therewith, shall remain in full force and effect.

3. Sharing of Expenses, Costs and Awards.

(a) The parties hereto agree that any damages award paid to or recovered by EAGLE in the arbitration styled “Eagle Pharmaceutical, Inc. v. The Medicines Company, American Arbitration Association Case# 13 122 Y 02642” (the “Arbitration”) shall be [*] by EAGLE and SCIDOSE; provided, however, that, prior to the distribution of any portion of such award to SCIDOSE, EAGLE shall deduct from such award the following:

(i) [*] paid by EAGLE to Xxxxxxxxx Xxxxxxx LLP in respect of the Arbitration through June 30. 2013 (subject to later true up) including [*] as set forth on the exhibit attached hereto;

(ii) excluding fees set forth in Section 3(a)(i) above, any [*] payable by EAGLE to Xxxxxxxxx Traurig LLP in respect of the Arbitration;

(iii) subject to Section 4 below, [*]; and

(iv) [*] incurred in respect or the development and licensing of the bivalirudin and Arbitration support as set forth on Exhibit C attached hereto.

Payment of SCIDOSl’s portion of such award, if not paid directly by The Medicines Company to SCI DOSE, shall be remitted to SCIDOSE within [*] of payment by The Medicines Company.

(b) By way of example, if the award in the Arbitration equals [*], such award would be distributed as follows:

(i) To EAGLE, an amount equal to approximately [*] in reimbursement of amounts previously paid to Xxxxxxxxx Xxxxxxx as described in Section 3(a)(l) above, then

(ii) To Xxxxxxxxx Traurig, an amount equal to [*] in satisfaction of the amounts described in Section 3(a)(ii) above, then

(iii) To EAGLE, [*] to reimburse EAGLE fix costs incurred in respect of the Arbitration as described in Section 3(a)(iii) above, then

(iv) To EAGLE [*] to EAGLE to reimburse EAGLE for out- of-pocket expenses actually incurred as described in Section 3(a)(iv) above, then

(v) To the SCIDOSE PARTIES, [*], and to EAGLE, [*].

4. Side Letter Clarification. Pursuant to a side letter dated May 22, 2009 (the “2009 Side Letter’’), the parties hereto acknowledged that, subject to the terms of the 2009 Side Letter, EAGLE shall [*] in creating the 505(b)(2) Data (as defined in the 2009 Side Letter) related to the applicable 505(b)(2) Product (as defined in the 2009 Side Letter). The parties hereto hereby agree that, for purposes of the 2009 Side Letter, “[*] shall mean (i) for Angiomax®) (bivalirudin), [*] of any award in the Arbitration and (ii) for all other products developed and sold under the DEVELOPMENT AGREEMENTS,[*] of GROSS PROFIT (as defined in the DEVELOPMENT AGREEMENTS).

5. Aggregate Limitation on all Payments from EAGLE to SClDOSE PARTIES and AFFILIATES. The parties hereto agree that, during the 90-day period beginning on the date hereof they will negotiate in good faith the parameters, consideration and conditions around a [*] aggregate cap of amounts owed by EAGLE to the SCIDOSE PARTIES under the DEVELOPMENT AGREEMENTS.

6. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original and any of which shall constitute a single document. A facsimile (or pdf) signature of an authorized signatory of any party hereto shall be valid and binding and constitute due execution and delivery of this Agreement by such party hereto.

7. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of State of Delaware without regard to its conflict of law rules or principles.

[The remainder of this page has been intentionally left blank.]

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed and delivered by their respective proper and duly authorized representatives as of the date first set forth above.

EAGLE PHARMACEUTICALS, INC.


By:
	Name:	Xxxxx Xxxxxxx
	Title:	President and CEO


XXXXXX ONE, LLC


By:	/s/ Xxxxxx Xxxxx
	Name:	Xxxxxx Xxxxx
	Title:	President and CEO


SCIDOSE, LLC


By:	/s/ Xxxxxx Xxxxx
	Name:
	Title:


THERDOSE, LLC


By:	/s/Xxxxxx Xxxxx
	Name:
	Title:

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed and delivered by their respective proper and duly authorized representatives as of the date first set forth above.

EAGLE PHARMACEUTICALS, INC.


By:	/s/ Xxxxx Tariff
	Name:	Xxxxx Xxxxxxx
	Title:	President and CEO


XXXXXX ONE, LLC


By:	/s/ Xxxxxx Xxxxx
	Name:	Xxxxxx Xxxxx
	Title:	President and CEO


SCIDOSE, LLC


By:	/s/ Xxxxxx Xxxx
	Name:
	Title:

	THERDOSE, LLC


	By:	/s/ Xxxxxx Xxxxx
		Name:
		Title:

Exhibit A

List of Agreements between EAGLE and SCIDOSE PARTIES

Agreement Date		Development Partner
June 12, 2007		Development and License Agreement by and between Eagle Pharmaceuticals, Inc. and SciDose, LLC

September 24, 2007		Development and License Agreement by and between Eagle Pharmaceuticals, Inc. and SciDose, LLC

March 18, 2008		Development and License Agreement between Eagle Pharmaceuticals, Inc. and Xxxxxx One, LLC

February 13, 2009		Development and License Agreement between Eagle Pharmaceuticals, Inc. and Xxxxxx One, LLC

May 22, 2009		Letter Amendment — Eagle & SciDose / Xxxxxx One

March 18, 2008		Amendment No. 1 to Development and Licensing Agreement

March 25, 2008		Amendment No. 2 to Development and Licensing Agreement

November 20, 2009		Amendment

December 23, 2010		Letter Amendment — Eagle & SciDose / Xxxxxx one

December 3, 2008		Amendment No. 3 to Development and Licensing Agreement

Exhibit B

	$000’s	Commentary
BIVALIRUDIN ARBITRATION
Xxxxxxxxx Legal Expenses
Xxxxxxxxx Fees	[*]	Xxxxxxxxx Legal — [*]
*Xxxxxxxxx Out of Pocket	[*]	Xxxxxxxxx out of pocket — needs to be reconciled
*Estimated Total Payments made by Eagle through 6/30/13	*[]**

Exhibit C

	$000’s	Commentary
Bivalirudin
Milestone Payment	[*]	6/12/07 Agreement
OOP	[*]	Unreimbursed Eagle expenses (’07-’08)
Orrick — Contracting	[*]	Legal
FLH	[*]	Legal
Clotting	[*]	Clotting Study
*Estimated Total Payments made by Eagle through 6/30/13	*[]**

*All costs are subject to true up

Document Metadata

Table of Contents

DEVELOPMENT AND LICENSE AGREEMENT

Document Metadata